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Directed Evolution of Sortase Activity and Specificity 
 
Abstract 
 Nature employs complex networks of protein-tailoring enzymes to effect the post-
translational modification of proteins in vivo.  By comparison, modern chemical methods rely 
upon either nonspecific labeling techniques or upon the genetic incorporation of bioorthogonal 
handles.  To develop truly robust bioconjugates it is necessary to develop methods which possess 
the exquisite activity and specificity observed in biological catalysts.  One attractive strategy to 
achieve this is the engineering of protein-tailoring enzymes possessing user-defined specificity 
and high catalytic efficiency. 
 In Chapter Two, we describe a directed evolution strategy for enzymes that catalyze 
desired bond-forming reactions.  We then employed this system for the directed evolution of S. 
aureus sortase A (SrtA), a bacterial transpeptidase catalyzing the cleavage and re-ligation of a 
five amino acid peptide (Leu-Pro-Xxx-Thr-Gly) to a three amino acid acceptor sequence (Gly-
Gly-Gly).  Over the course of three rounds of mutagenesis and screening, we isolated variants of 
SrtA with up to a 140-fold increase in LPXTG-coupling activity compared with the starting wild-
type enzyme. 
 In Chapters Three and Four, we demonstrated the usefulness of this evolved SrtA variant 
(eSrtA) by using it to both generate, as well as to strip and regenerate, a surface consisting of the  
antithrombotic protein Thrombomodulin attached covalently to a synthetic base layer. By 
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appending a pentaglycine motif to a polyurethane catheter, we demonstrated that eSrtA catalyzed 
the covalent attachment of a C-terminally LPETG-ylated antithrombotic protein, even in whole 
blood.  We further demonstrated that this protein layer could be removed by subsequent 
treatment with eSrtA, then washed and recharged with fresh LPETG-tagged protein in vivo. 
 In Chapter Five, we further developed the selection scheme described in Chapter One, 
and applied it to the evolution of eSrtA variants with dramatically altered substrate specificities.  
Applying a technique of competitive inhibition led to the evolution of two new eSrtA variants, 
recognizing LPESG and LAETG but not LPETG with up to a 51,000-fold change in substrate 
specificity.  Finally, we demonstrate that these novel SrtA derivatives enable the synthesis of 
new classes of materials, the streamlined construction of complex bioconjugates and the direct 
functionalization of endogenous human proteins without the use of genetic manipulation. 
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Introduction  
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Abstract 
Gram-positive bacteria possess complex peptidoglycan cell walls contained in a 
periplasmic space between their inner and outer membranes.  Serving multiple functions, the cell 
wall is in many cases modified with different protein components in order to facilitate its 
catalytic as well as structural role in bacterial physiology.  This dynamic incorporation of cellular 
proteins is facilitated by the bacterial sortases, a class of enzymes which catalyze the direct 
cleavage and transpeptidation of peptide sorting sequences onto target anchor substrates, and 
come in multiple flavors corresponding to their particular substrates and functional roles.  
Following the discovery that the catalytic domain of S. aureus sortase A (SrtA) could catalyze 
the post-translational conjugation of C-terminal Leu-Pro-Xxx-Thr-Gly (where Xxx=any amino 
acid) moieties onto N-terminal Gly-Gly-Gly peptides, there has been a flurry of interest in using 
it for the synthesis of otherwise synthetically intractable protein conjugates.  However, its poor 
kinetics and rigidly defined substrate scope have greatly limited SrtA’s applications in the 
broader research community.  In this chapter, we first review the discovery and physiological 
role of bacterial sortases, then examine prior investigations into the enzymology, structure and 
inhibition of SrtA.  Finally, we briefly review current techniques in bioconjugate chemistry, and 
applications of SrtA to the synthesis of novel bioconjugates. 
 
The Physiological Role of Sortases 
 The cell wall of gram-positive bacteria is a complex, extracellular organelle which 
envelops its maintaining organism and in turn may present a variety of species- and strain-
specific factors to its surrounding environment.
1
  These factors are important for many host-
pathogen interaction
2-6
, including bacterial adhesion to eukaryotic cells
3,4
 and extracellular 
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matrix
5,6
, and may be additionally involved in the evasion of immune responses
7
 by pathogenic 
bacteria.  Given this plurality of functions, it is therefore desirable that the machinery for 
installation of proteins into the cell wall be robust to extracellular conditions as well as capable 
of dynamic regulation in order to adjust the milieu of factors presented to the extracellular 
environment. 
 S. aureus sortase A was discovered by Mazmanian et al
8
 following the isolation of strains 
defective in the anchoring of cell wall proteins, however the LPXTG sorting signal was known 
from prior molecular biological
9
 and proteolytic
10
 characterization of the protein component of 
the peptidoglycan cell wall.  Research into the homologous S. aureus sortase B (SrtB) gene 
suggested its importance in the capture of heme from its local environment, derived from its role 
in anchoring the ferrichrome transporter IsdC
11,12
.  Further analysis of the Isd locus, as well as 
biochemical characterization of SrtB, revealed it to catalyze the same sorting substrate/lipid II 
conjugation reaction as SrtA, but with an aberrant, NPQTN sorting specificity.
11
  These results 
collectively suggested the regulatory nature of sortases, with the expression of each enzyme 
controlling dynamically the composition of the bacterial cell wall. 
Subsequent computational analysis suggested the presence of three other families of 
sortase genes including variants in gram negative bacteria
13,14
, with many species employing 
different sorting motifs from the canonical LPXTG
15
.  Simultaneous investigation of gram-
positive pilus biochemistry suggested that several of these sortases were responsible for the 
polymerization of protein precursors to form bacterial pili, ultimately anchored to the cell wall
16
.  
This, coupled with the presence of sortase genes in every sequenced gram positive bacterial 
strain to date, suggests that these enzymes are the primary determinants of cell wall covalency in 
gram positive bacteria. 
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Structural and Mechanistic Studies of S. aureus sortase A 
 Given their fundamental role in bacterial physiology and their lack of sequence homology 
to known eukaryotic proteins, sortases have presented a compelling target for structural and 
mechanistic study.  Consequently, the apo-SrtA crystal
17
 and NMR
18
 structures were determined 
shortly after its discovery.  However, the lack of structure in the LPXTG binding region of the 
enzyme provided little insight into the binding modes of SrtA (Figure 1-1).  Similarly, the distal 
binding of LPXTG in attempted co-crystal structures of the LPXTG/SrtA structure led to 
Figure 1-1 The NMR ensemble structure of substrate-unbound S. aureus sortase A 
The catalytic cysteine residue is shown in blue, the catalytic histidine is shown in orange.  The 
substrate binding channel is located down the center of the image, with the β6-7 substrate binding loop 
unstructured, at left. 
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significant early controversy as to SrtA’s detailed chemical mechanism.  Conservation across all 
known sortases suggested the essential roles of the catalytic residues Cys184 and His120, a 
hypothesis supported by early alanine screening experiments.
19,20
   
This observation taken with the close proximity of Arg197 to the enzyme’s putative 
active site and the reactivity of the enzyme to the thiolate-reactive small molecule MTSET 
suggested a cysteine protease-like mechanism whereby His120 deproto nates Cys184 to generate 
Figure 1-2 The NMR ensemble structure of the LPAT-charged intermediate S. aureus sortase A 
The catalytic cysteine residue is shown in blue, the catalytic histidine is shown in orange.  The LPAT 
substrate is attached via a disulfide linker to the active site cysteine, and is shown in red.  The bound 
calcium ion is shown as a grey sphere 
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a thiolate, with Arg197 generating an oxyanion hole to facilitate overall catalysis.  This idea was  
drawn into question when it was found that substituting Arg197 by citrulline, an analog which 
retains arginine’s hydrogen bonding properties but lacks its positive charge.  On synthesizing this 
SrtA variant b y a combination of solid phase peptide synthesis and native chemical ligation, 
Bentley et al found that it retained nearly all of SrtA’s native activity.21 Together with detailed  
kinetic measurements and the enzyme’s apparent pH independence22 these data collectively 
support an alternate mechanism, whereby a rare (ca 0.06% of all enzymes) thiolate-containing 
SrtA forms an unstable tetrahedral intermediate which is subsequently protonated by the adjacent 
Figure 1-3 The positioning of Arg197 enforces a horseshoe conformation on the bound LPXTG 
peptide 
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His120.  This leads to the formation of an exceptionally stable thioester intermediate between 
Cys184 and the threonine residue of the sorting signal, and the ejection of the C-terminal glycine 
residue of the sorting signal.  Subsequent binding of an N-terminal GGG motif leads to the 
reverse reaction of this taking place, wherein the thioester is attacked by the deprotonated amine 
terminus of GGG to yield a new conjugate (Figure 1-4).   
Unusually,  Arg197 appears to function only as a hydrogen bond donor, serving to 
position the peptide substrate for attack in this reverse protonation mechanism
21
.  This hypothesis 
was essentially confirmed in the holo-NMR structure of SrtA (Figure 1-2), determined with a 
Figure 1-4 The Reverse Protonation Mechanism of S. aureus SrtA 
The Arg197 residue makes hydrogen bonding contacts with the LPXTG backbone, orienting it for attack 
by the Cys120 thiolate.  Protonation of the leaving glycine moiety by His120 leads to the ejection of the 
sorting signal’s C-terminal glycine moiety and the formation of a stable Cys120 thioester intermediate.  
The reverse reaction, wherein an N-terminal glycine residue resolves the thioester and forms a new 
LPXTG peptide, proceeds via the reverse mechanism 
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covalently linked LPAT moiety to mimic the enzyme’s catalytic intermediate, with Arg197 
forming hydrogen bonds along a horseshoe-shaped peptide conformation (Figure 1-3).  This is 
further facilitated by the behavior of the β6-7 binding loop in SrtA, which is normally 
unstructured, but rigidifies on binding of a calcium ion to facilitate binding of the LPXTG 
sorting signal
23
.  
 In light of their physiological importance, periplasmic expresion and biochemically 
unique mechanism, then, sortases make for compelling targets for antibiotic discovery.  Such 
notions are well supported by literature precedent, as ΔsrtA and ΔsrtB knockouts of S. aureus 
show abrogated binding to various eukaryotic cellular, ECM and immune components
24
 and 
exhibit considerably diminished virulence in mouse models
24,25
.  Indeed, there have been 
multiple academic discovery efforts aimed at identifying inhibitors of SrtA and related 
transpeptidases
26-33
, and while no reversible inhibitors have risen above micromolar-scale 
Figure 1-5 Selected Inhibitors of SrtA 
Top row: Reversible inhibitors, Bottom row: Covalent inhibitors.   
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inhibition of the enzyme, irreversible covalent modification of the catalytic cysteine in S. aureus 
SrtA has proven effective at the nanomolar scale, both via disulfide-mediated crosslinking
27
 as 
well as by a β-dimethylamino ketone that is converted into an α-β unsaturated ketone by the 
action of the enzyme
30
 (Figure 1-5).  That trans-micromolar inhibition has only been achieved by 
covalent inhibitors is unsurprising in light of SrtA’s unique enzymology – the enzyme’s 
dynamically unstructured binding site and small fraction of reaction-competent enzymes 
collectively makes access by traditional small molecule drug candidates extremely challenging.  
It also presents the unique situation where inhibition has little effect in cell proliferation assays, 
as ΔsrtA knockouts show little change in growth phenotype19 but dramatic changes in 
virulence
24,25
, septic arthritis and biofilm formation
34
.  Such subtle phenotypes demand either 
carefully constructed phenotypic assays or the use of targeted drug discovery efforts. 
The use of S. aureus SrtA in bioconjugate synthesis 
 Given SrtA’s efficacy in vivo, it is unsurprising that it was rapidly co-opted by the 
biotechnology community for use in protein-peptide ligation
35
, protein-PEG
36
 and peptide-
peptide nucleic acid
37
 conjugate synthesis.  Though conceptually similar, these initial reports 
were not widely adopted until the development of streamlined techniques for protein labeling by 
Popp et al
38
 later on.  This publication opened the floodgates for using SrtA to append a wide 
variety of small molecule modifiers onto proteins of interest, including lipidation
39-41
, 
aminoglycoside conjugation
42
, photocleavable handle conjugation
38
, biotinylation
38,43
, 
fluorophore conjugation
43-45
, bioorthogonal handle introduction
46
, and protein circularization
47
.  
Additionally, the S. pyogenes SrtA isoform was found to react with tri-alanine probes and the 
LPXTA tag
48,49
, a feature which has been exploited for the separate bifunctionalization of N- and 
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C-terminal protein tags
50
 as well as the introduction of bioorthogonal handles in circularized 
proteins
51
.   
Such approaches clearly show the power of sortagging as a ligation scheme, however the 
technique is historically hampered by several key limitations.  The poor enzymatic efficiency of 
both the S. aureus SrtA
52
 catalytic domain (kcat/Km ~ 120 M
-1
s
-1
) as well as the orthogonal S. 
pyogenes SrtA
48
 catalytic domain (kcat/Km ~ 12 M
-1
s
-1
) necessitate the use of stoichiometric, 
rather than catalytic amounts of these reagents.  The high stability of the thioester intermediate 
formed during the SrtA catalytic cycle, therefore, soaked away large fractions of the available 
substrate pool, leading to reduced yields and greatly increased the complexity of purifying away 
both excess SrtA and substrate-SrtA intermediates from the final reaction mixture.  Additionally, 
this slow catalysis prevented the use of SrtA in the conjugation of otherwise unstable chemical 
modifiers, such as thioesters
53
.   
More generally, the low catalytic activity of SrtA often made it a poor substitute for high-
efficiency chemical methods such as the copper-catalyzed click reaction
54-57
 (k ~ 10-200 M
-1
s
-1
) 
or copper-free click reaction
57-61
 (k ~ 10
-2
-1 M
-1
s
-1
).  In each case, the poor activity of SrtA can 
often overcome its biocompatibility and easy substrate synthesis, making either of these (in 
addition to other
57
) reaction chemistries the more attractive option for bioconjugate synthesis in 
vivo and in vitro.  Additionally, with the advent of genetically encodable click handles, these 
approaches enjoy very broad applicability, as tags can be incorporated more or less arbitrarily 
into target protein sequences.  These approaches are not without their drawbacks, however, as 
modern genetic encoding techniques rely upon competition of native protein translation 
termination factors with engineered tRNA machinery, leading to any cellular expression system 
producing a mixture of mislabeled, truncated, and correctly charged proteins
61
.  Additionally, the 
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copper-catalyzed version of the click reaction is not, in principle, biocompatible due to the 
toxicity of the requisite Cu(I) ion, while the copper-free version relies upon the synthesis of 
complex cyclooctyne moieties that in general very low-yielding.  SrtA, with its facile substrate 
synthesis and biocompatible reaction conditions, would present a very appealing alternative to 
these approaches, were a more catalytically active variant with programmable specificity to be 
developed. 
To this end, there have been two major published investigations into changing the 
substrate specificity of S. aureus SrtA.  In the first, the β6-7 loop of SrtA was replaced by the 
homologous binding loop from S. aureus sortase B, in order to test if the NPQTN substrate 
specificity of SrtB could be added to SrtA
62
.  In this case, it was found that this altered enzyme 
possessed greatly (>5000-fold) diminished catalytic efficiency, but now accepted NPQTN 
sequences preferentially over LPETG.  While the low activity of this variant made studying its 
detailed kinetics intractable, let alone using it as a molecular tool, it served as a valuable proof of 
principle for later efforts, including those reported in this thesis.  A more recent study attempted 
to evolve SrtA variants with altered specificity by randomizing the amino acid sequence of this 
binding loop, displaying the resulting variants as fusions to protein III in the bacteriophage M13, 
and then attempting to pull down variants capable of ligating biotinyl-FPETG peptides onto 
themselves
63
.  The variants isolated by this method also showed greatly (>10-fold) diminished 
catalytic activity relative to SrtA, but nonetheless showed largely ablated specificity at the first 
residue of the sorting signal.  These promiscuous variants nevertheless proved to be effective for 
the semisynthesis of histone H3 at low efficiency. 
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Abstract 
The ability to routinely generate efficient protein catalysts of bond-forming reactions 
chosen by researchers, rather than nature, is a longstanding goal of the molecular life sciences. 
Here we describe a directed evolution strategy for enzymes that catalyze, in principle, any bond-
forming reaction. The system integrates yeast display, enzyme-catalyzed bioconjugation, and 
fluorescence-activated cell sorting to isolate cells expressing proteins that catalyze the coupling 
of two substrates chosen by the researcher. We validated the system using model screens for 
Staphylococcus aureus sortase A-catalyzed transpeptidation activity, resulting in enrichment 
factors of 6,000-fold after a single round of screening. We applied the system to evolve sortase A 
for improved catalytic activity. After eight rounds of screening, we isolated variants of sortase A 
with up to a 140-fold increase in LPETG-coupling activity compared with the starting wild-type 
enzyme. An evolved sortase variant enabled much more efficient labeling of LPETG-tagged 
human CD154 expressed on the surface of HeLa cells compared with wild-type sortase. As the 
method developed here does not rely on any particular screenable or selectable property of the 
substrates or product, it represents a powerful alternative to existing enzyme evolution methods. 
Introduction 
 Despite the many attractive features of protein enzymes as catalysts for organic 
synthesis
2
, as research tools
3-5
, and as an important class of human therapeutics
6,7
, the extent and 
diversity of their applications remain limited by the difficulty of finding in nature or creating in 
the laboratory highly active proteins that catalyze chemical reactions of interest. A significant 
fraction of protein catalysts currently used for research and industrial applications was obtained 
through the directed evolution of natural enzymes
8
. Current methods for the directed evolution of 
enzymes have resulted in some remarkable successes
9,10
, but generally suffer from limitations in 
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reaction scope. For example, screening enzyme libraries in a multi-well format has proven to be 
effective for enzymes that process chromogenic or fluorogenic substrates, and is typically limited 
to library sizes of ~10
2
-10
6
 members, depending on the nature of the screen and on available 
infrastructure
11
. Selections of cell-based libraries that couple product formation with auxotrophy 
complementation
12
 or transcription of a reporter gene
13
 enable larger library sizes to be 
processed, but also suffer from limited generality because they rely on specific properties of the 
substrate or product. Likewise, in vitro compartmentalization is a powerful genotype-phenotype 
co-localization platform that has been used to evolve protein enzymes with improved turnover, 
but also requires corresponding screening or selection methods that thus far have been substrate- 
or product-specific
14
. 
Directed evolution strategies that are general for any bond-forming reaction would 
complement current methods that rely on screenable reactions or selectable properties of the 
substrate or product. In principle, chemical complementation using an adapted yeast three-hybrid 
assay is reaction-independent
15
, but requires membrane-permeable substrates and offers limited 
control over reaction conditions because the bond-forming event must take place intracellularly. 
Phage-display and mRNA-display systems that are general for any bond-forming reaction have 
been used to evolve enzymes including DNA polymerases
16
 and RNA ligases
17
. These 
approaches also offer advantages of larger library sizes and significant control over reaction 
conditions because the enzymes are displayed extracellularly or expressed in the absence of a 
host cell.  
Cell surface display 
18-21
 is an attractive alternative to phage and mRNA display. In 
contrast with other display methods, the use of bacterial or yeast cells enables up to 100,000 
copies of a library member to be linked to one copy of the gene, increasing sensitivity during 
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screening or selection steps. In addition, cell surface-displayed libraries are compatible with 
powerful fluorescence-activated cell sorting (FACS) that enable very large libraries to be 
screened efficiently (>10
7
 cells per hour) with precise, quantitative control over screening 
stringency. The multicolor capabilities of FACS also enable normalization for enzyme display 
level during screening and simultaneous positive and negative screens, capabilities that are 
difficult to implement in phage and mRNA display. 
In this work we integrated yeast display, enzyme-catalyzed small molecule-protein 
conjugation, and FACS into a general strategy for the evolution of proteins that catalyze bond-
forming (coupling) reactions. We applied the system to evolve the bacterial transpeptidase 
sortase A for improved catalytic activity, resulting in sortase variants with up to 140-fold 
improvement in activity. In contrast with wild-type sortase, an evolved sortase enabled highly 
efficient cell-surface labeling of recombinant human CD154 expressed on the surface of live 
HeLa cells with a biotinylated peptide. 
Results 
 Design and Implementation of a General System for the Evolution of Bond-Forming Enzymes 
22 
 
The enzyme evolution system is overviewed in Figure 2-1. Yeast cells display the 
enzyme library extracellularly as a fusion to the Aga2p cell surface mating factor, which is 
covalently bound to the Aga1p mating factor with a reactive handle that enables covalent 
attachment of substrate A to cells. We chose the S6 peptide
4
 as the reactive handle to link 
substrate A to cells using Sfp phosphopantetheinyl transferase from Bacillus subtilis. Substrate B 
linked to an affinity handle (e.g. biotin, represented by the gray circle in Figure 2-1) is added to 
the substrate A-conjugated yeast display enzyme library. Due to the high effective molarity of 
substrate A with respect to each cell’s displayed library member, both of which are immobilized 
on the cell surface, active library members will predominantly catalyze the pseudo-
intramolecular A–B bond formation between affinity handle-linked substrate B and substrate A 
molecules on their own host cell. The intermolecular coupling of substrate B with substrate A 
Figure 2-1 A general strategy for the evolution of bond-forming catalysts using yeast display. 
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molecules attached to other cells is entropically much less favorable, and therefore yeast cells 
displaying inactive enzymes should remain predominantly uncoupled to the affinity handle. 
Following incubation with substrate B for the desired reaction time, cells are stained with 
a fluorescent molecule that binds the affinity handle (e.g., streptavidin-phycoerythrin 
(streptavidin-PE)). The most fluorescent cells, which encode the most active catalysts, are 
isolated by FACS. Up to 10
8
 cells can be sorted in a two-hour period using modern FACS 
equipment. After sorting and growth amplification, the recovered cells can be enriched through 
additional FACS steps, or DNA encoding active library members can be harvested and subjected 
to point mutagenesis or recombination before entering the next round of evolution. 
We used a chemoenzymatic approach to link substrate A to cells rather than a non-
specific chemical conjugation strategy to more reproducibly array the substrate on the cell 
surface and to avoid reagents that might alter the activity of library members. The B. subtilis Sfp 
phosphopantetheinyl transferase catalyzes the transfer of phosphopantetheine from coenzyme A 
(CoA) onto a specific serine side chain within an acyl carrier protein or peptide carrier protein. 
We chose Sfp to mediate substrate attachment because of its broad small-molecule substrate 
Sfp phosphopantetheinyl transferase 
     S6 peptide 
(GDSLSWLLRLLLN)  (R = biotin-PEG, fluorescein, porphyrin, glutathione, LPETG, GGG, any generic substrate A, etc.) 
Figure 2-2 Sfp-catalyzed transfer of phosphopantetheinyl derivatives (blue) onto a specific serine 
residue (underlined) within the S6 peptide sequence. 
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tolerance
4,22
  and its ability to efficiently conjugate phosphopantetheine derivatives to the 12-
residue S6 peptide
23
 (Figure 2-2). We speculated that the small size of the S6 peptide would 
allow it to be well-tolerated in the context of the Aga1p mating factor. Functionalized CoA 
derivatives can be readily prepared by reacting the free thiol of commercially  
available CoA
4,22
 with a commercially available maleimide-containing bifunctional crosslinker, 
followed by substrate A bearing a compatible functional group. 
enzyme 
S6 peptide 
Aga2p 
S S 
S S 
Aga1p 
Aga2p HA linker myc enzyme 
GAL 
Aga2p linker HA myc enzyme 
GAL TEV site 
Aga1p 
Aga1p S6 
GPD 
GAL 
pCTcon2 plasmid 
transform 
integrate into 
S. cerevisiae 
BJ5465 genome 
yeast cell wall 
induce display with 
galactose 
Figure 2-3 Engineering a Saccharomyces cerevisiae strain that simultaneously displays the S6 
peptide sequence and the sortase enzyme library on its cell surface 
The S6-Aga1p construct is cloned under the control of the constitutive glyceraldehyde-3-phosphate 
dehydrogenase (GPD) promoter and integrated into the genome of S. cerevisiae BJ5465 to yield strain 
ICY200. Through several cloning steps, a TEV recognition site is inserted between the HA tag and 
enzyme gene of the Aga2p fusion construct. Yeast display of sortases is induced upon the addition of 
galactose to the media.  
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To integrate Sfp-catalyzed bioconjugation with yeast display required engineering a new 
yeast display vector and yeast strain (Figure 2-3).  To create a handle for substrate attachment at 
the cell surface, we fused the S6 peptide onto the N-terminus of Aga1p and integrated this 
construct under the control of the strong, constitutive GPD promoter in the genome of 
Saccharomyces cerevisiae strain BJ5465
20
. We modified the Aga2p expression construct by 
inserting the recognition site for tobacco etch virus (TEV) protease between the hemagglutinin 
(HA) tag and the coding sequence of the protein of interest. Following incubation of the 
Figure 2-4 Validation of the enzyme evolution strategy. 
(A) FACS histogram of the reaction between cell surface-conjugated LPETGG and free GGGYK-
biotin catalyzed by yeast-displayed wild-type S. aureus sortase A (wt srtA). Cells were stained with 
streptavidin-PE and an AlexaFluor488-anti-HA antibody. Negative control reactions with either the 
inactive C184A srtA mutant or without LPETGG are shown. (B) Dot plots comparing PE 
fluorescence (extent of reaction) vs. AlexaFluor488 fluorescence (display level) for two model 
screens. Mixtures of cells displaying either wt srtA or the inactive C184A srtA (1:1000 and 1:100 
wt:C184A) were processed as in (A), then analyzed by FACS. Cells within the specified gate (black 
polygon) were collected. (C) Model screening results. Gene compositions before and after sorting 
were compared following HindIII digestion, revealing strong enrichment for active sortase. 
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substrate-A-conjugated yeast library with substrate B, TEV protease digestion removes all 
library members from the surface, including any undesired enzymes that bind or react directly 
with substrate B, but do not catalyze A–B bond formation, thus removing a potential source of 
undesired background. The HA tag remains on the cell surface and enables staining for enzyme 
display level using an anti-HA antibody. The ability to efficiently cleave enzymes from the yeast 
cell surface also facilitates enzyme characterization in a cell-free context. 
  
Validation of the Yeast Display System 
A 
SMCC coenzyme A (CoA-SH, R=H) 
1. SMCC, then CoA-SH 
2. 20% piperidine 
Fmoc−GGGK−CONH2 
NH3
NH2−YLELPETGG−CONH2 
1. SMCC; HPLC purify 
2. CoA-SH 
NH2−GGGK−CONH2 
GGGK-CoA 
N−YLELPETGG−CONH2 
H 
CoA-LPETGG 
C 
B 
Figure 2-5 Synthesis of coenzyme A-conjugated sortase substrates.  
(A) Chemical structures of the SMCC crosslinker and coenzyme A (CoA). (B) Synthesis strategy for 
GGGK-CoA. (C) Synthesis strategy for CoA-LPETGG. 
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Sortase A (srtA) is a sequence-specific transpeptidase found in Staphylococcus aureus 
and other Gram positive bacteria. The S. aureus enzyme recognizes a LPXTG site (X = any 
amino acid), cleaves the scissile amide bond between threonine and glycine using a nucleophilic 
cysteine (C184), and resolves the resulting acyl-enzyme intermediate with oligoglycine-linked 
molecules to generate the fusion of the LPXT- and oligoglycine-linked peptides or proteins. 
Sortase A-catalyzed transpeptidation has emerged as a powerful tool for bioconjugation because 
of the enzyme’s high specificity for the LPXTG motif and its extremely broad substrate tolerance 
outside of the recognition elements described above. Because the LPXTG and oligoglycine 
motifs can be flanked by virtually any biomolecule, sortase has been used to label proteins, 
generate nucleic acid-protein conjugates, and immobilize proteins onto solid supports
24
. A 
significant limitation of srtA is the large quantities of the enzyme or long reaction times that are 
needed to overcome its poor reaction kinetics (kcat/Km LPETG = 200 M
-1
 s
-1 
, Table 1). The 
evolution of a more active S. aureus srtA would therefore significantly enhance the utility and 
scope of this bond-forming reaction. 
We first examined if yeast-displayed sortase enzymes in our system could catalyze the 
reaction between surface-immobilized LPETGG and exogenous biotinylated trigycine peptide 
(GGGYK-biotin). To conjugate cells to the LPETGG substrate, we incubated yeast displaying 
wild-type srtA and the S6 peptide with Sfp and coenzyme A-linked LPETGG (CoA-LPETGG, 
Figure 2-5). The sortase-catalyzed reactions were initiated with the addition of GGGYK-biotin 
and 5 mM CaCl2. After washing, the cells were stained with streptavidin-PE and an 
AlexaFluor488-conjugated anti-HA antibody to analyze the extent of reaction and enzyme 
display level, respectively, by flow cytometry. When yeast cells displaying wild-type sortase A 
(wt srtA-yeast) were analyzed, the majority of the cells exhibited high levels of PE fluorescence, 
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indicating substantial conjugation with GGGYK-biotin (Figure 2-4A). In contrast, wt srtA-yeast 
not conjugated to LPETGG, or LPETGG-conjugated yeast cells displaying the inactive C184A 
sortase mutant, exhibited only background levels of PE fluorescence after incubation with 
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Figure 2-6 Additional model screening results. 
(A) The indicated wt:C184A srtA-yeast mixtures were modified with GGGK-CoA, incubated with 50 μM 
biotin-LPETGG for 15 minutes, and sorted as described in Figure 2. Analysis of the gene compositions 
before and after sorting by HindIII digestions reveals an enrichment factor of ~3,500-15,500 after a single 
round of sorting. (B) Yeast simultaneously displaying the AviTag sequence and wild-type E. coli biotin 
ligase (BirA) or its less active R317E mutant1  were mixed in 1:1000 and 1:100 BirA:R317E ratios. The 
mixtures were incubated with unmodified streptavidin to silence the biotinylation signal that arises from 
BirA-catalyzed biotinylation of the AviTag within the yeast secretory pathway during induction. The cells 
were treated with 1 μM biotin, 5 mM MgCl2, and 0.2 mM ATP at room temperature for one hour. 
Following streptavidin-PE staining, the cells were subjected to FACS and the cells that exhibit the top 
0.07% and 0.55% PE fluorescence intensities for the 1:1000 and 1:100 screens, respectively, were 
collected. Analysis of gene compositions before and after sorting by HindIII digestions reveals an 
enrichment factor of ~3,500-15,500 after one single round of sorting. 
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GGGYK-biotin, confirming that biotinylation was dependent both on sortase activity and on the 
presence of both substrates (Figure 2-4A). 
To verify that enzymes displayed on the yeast cell surface catalyze pseudo-intramolecular 
reactions with substrate molecules immobilized on the same cell, we performed one round of 
model screening on mixtures of wt srtA-yeast and srtA C184A-yeast. Yeast cells were mixed in 
1:100 and 1:1000 ratios of wt:C184A sortases. Each mixture of cells was coupled with CoA-
LPETGG using Sfp, then incubated with 50 μM GGGYK-biotin for 15 minutes. Because srtA 
binds weakly to GGG (Km = 140 μM, Table 1), washing with non-biotinylated GGG was 
sufficient to remove any background signal and TEV digestion was not performed after the 
reaction. After fluorophore staining, cells exhibiting both AlexaFluor488 and PE fluorescence 
were isolated by FACS (Figure 2-4B) and amplified by culturing to saturation. The plasmid 
DNA encoding survivors was harvested, and the compositions of the recovered genes were 
analyzed by restriction digestion with HindIII following PCR amplification. The wt srtA gene is 
distinguishable from C184A by the presence of an additional HindIII site (Figure 2-4C). In both 
model FACS sort experiments, we observed ≥ 6,000-fold enrichment of the wild-type gene from 
both mixtures that were predominantly the inactive C184A mutant (Figure 2-4C). Similarly high 
enrichment factors were also observed in model sortase screens in which GGG-modified cells 
were reacted with biotinylated LPETGG peptide, and in model biotin ligase (BirA) screens in 
which cells displaying a biotinylation substrate peptide and wild-type BirA were enriched in the 
presence of a large excess of cells displaying a less active BirA mutant (Figure 2-6). These 
results collectively suggest that this system can strongly enrich yeast displaying active bond-
forming enzymes from mixtures containing predominantly yeast displaying inactive or less 
active enzyme variants. 
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Directed Evolution of Sortase A Enzymes with Improved Catalytic Activity 
 Next we sought to evolve S. aureus srtA for improved activity using the enzyme 
evolution strategy validated above. We focused on improving the poor LPXTG substrate 
recognition of srtA (Km = 7.6 mM, Table 1), which limits the usefulness of sortase-catalyzed 
bioconjugation by requiring the use of high concentrations of enzyme (> 30 μM) or long reaction 
times to compensate for poor reaction kinetics at the micromolar concentrations of LPXTG 
substrate that are typically used. To direct evolutionary pressure to improve LPXTG recognition, 
we formatted the screen such that the triglycine substrate is immobilized on the cell surface 
along with the enzyme library, and the biotinylated LPETG peptide is added exogenously. This 
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Figure 2-7 FACS enables precise definition of sort gates using parallel control samples 
In this example, yeast cells displaying clone 4.2 were subjected to identical reaction conditions and FACS 
analysis protocols as the cells recovered after R6, enabling the creation of a sort gate (black polygon) that 
isolates mutants with higher specific activity than clone 4.2 in the R7 sort. The percentage of cells 
residing within the sort gate is shown. 
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format enables evolutionary pressure for improved LPETG recognition to be increased simply by 
lowering the concentration of LPETG peptide provided during the sortase-catalyzed bond-
forming reaction. 
 
Figure 2-8 Reaction conditions and sorting parameters used to evolve sortase enzymes with 
improved catalytic activity. 
We randomly mutated the wt S. aureus srtA gene using PCR with mutagenic dNTP 
analogs
25
 and cloned the resulting genes into the modified yeast display vector using gap repair 
homologous recombination to yield a library of ~10
8
 transformants (round 0, R0). Each library 
member contained an average of two non-silent mutations. The library was subjected to four 
rounds of enrichment for sortase activity without any additional diversification between rounds. 
In each round we subjected control samples— cells displaying wt srtA, or the cells isolated from 
the previous round— to identical reaction conditions and screening protocols to precisely define 
substrate A-
CoA 
biotin-substrate B, 
concentration 
reaction 
 time 
cells 
sorted 
cells 
recovered 
R0 (diversity: 7.8x107)  
R1 GGGK-CoA Biotin-LPETGS, 100 µM 60 min 6.0x108 8.5x106 
R2 GGGK-CoA Biotin-LPETGG, 10 µM 60 min 1.2x108 1.2x106 
R3 GGGK-CoA Biotin-LPETGS, 1 µM 60 min 2.5x107 1.3x105 
R4 GGGK-CoA Biotin-LPETGG, 100 nM 15 min 1.3x107 2.0x104 
R4Shuf (diversity: 6.9x107)  
R5 GGGK-CoA Biotin-LPETGG, 100 nM 45 min 4.0x108 6.0x106 
R6 GGGK-CoA Biotin-LPETGS, 100 nM 30 min 1.2x108 4.7x105 
R7 GGGK-CoA Biotin-LPETGG, 10 nM 15 min 2.5x107 6.9x105 
R8 GGGK-CoA Biotin-LPETGG, 10 nM 5 min 1.0x107 2.0x104 
R9 CoA-LPETGG GGGYK-biotin, 100 nM 5 min 7.5x106 6.0x103 
R8mut (diversity: 5x107) 
R9mut CoA-LPETGG GGGYK-biotin, 1 µM 15 min 6.7x107 9.7x104 
R10mut CoA-LPETGG GGGYK-biotin, 100 nM 10 min 1.25x107 2.8x104 
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FACS gates that captured cells with PE fluorescence corresponding to improved sortase activity 
(Figure 2-7).  We applied increasing evolutionary pressure for improved LPETG recognition by 
decreasing the concentration of biotinylated LPETG substrate 10-fold with each successive 
round, starting from 100 μM in the first round and ending with 100 nM in the fourth round 
(Figure 2-8). We also increased evolutionary pressure for overall catalytic activity by accepting a 
smaller percentage of the most PE-fluorescent cells with each successive round, ranging from 
1.4% in R1 to 0.15% in R4, and by shortening the reaction time in R4 from 60 to 15 minutes.  
To preclude the evolution of specificity for a particular LPETG-containing sequence, we 
alternated using biotin-LPETGS (R1 and R3) and biotin-LPETGG (R2 and R4) peptides. After 
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Sfp-catalyzed labeling of yeast cells using biotin-CoA/GGGK-CoA mixtures 
Figure 2-9  
The relative amount of biotinylated CoA adduct in the supernatant is reflected by cell-surface 
fluorescence after Sfp-catalyzed conjugation to yeast cells and streptavidin-PE staining. Biotin-CoA was 
mixed with GGGK-CoA in various molar ratios. A suspension of ICY200 cells at a density of 2.5×107 
cells/mL was incubated with 6 μM Sfp and 5 μM total concentration of CoA conjugate. The fluorescence 
of the cells after streptavidin staining was measured using flow cytometry. 
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the fourth round of enrichment, surviving genes were subjected to in vitro homologous 
recombination using the NExT procedure
26
 and re-cloned into yeast to yield a recombined and 
diversified library of ~10
8
 transformants. The shuffled library (R4Shuf) was subjected to four 
additional rounds of sorting (resulting in R5, R6, R7, and R8), with the concentration of 
biotinylated LPETG peptide dropping from 100 nM to 10 nM in the final round (Figure 2-8). 
 We developed an assay to rapidly compare the activity of yeast-displayed sortase 
mutants. Yeast ce lls were incubated with TEV protease to release the enzymes from the cell 
surface into the surrounding supernatant. The reaction in the supernatant was initiated by the 
addition of the two peptide substrates, CoA-LPETGG and GGGYK-biotin. After 30 minutes of 
reaction, Sfp was added to the same reaction mixture to attach the biotinylated adduct and 
unreacted CoA-LPETGG onto the cell surface. We verified that the level of cell-surface 
fluorescence after streptavidin-PE staining is a direct reflection of the relative amount of 
Figure 2-10. Activity assays of mutant sortases.  
(A) Yeast pools recovered from the sorts were treated with TEV protease, and the cleaved enzymes 
were assayed for their ability to catalyze coupling between 5 μM CoA-LPETGG and 25 μM GGGYK-
biotin. (B) Yeast cells expressing select individual clones were treated as described above. Error bars 
represent the standard deviation of three independent experiments. 
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biotinylated product in so lution (Figure 2-9). 
 We evaluated the mean activity of the yeast pools recovered after each round of sorting 
using this assay. Over the course of the selections, we observed a steady increase in the extent of 
product formation catalyzed by the recovered sortase mutants. By the last round (R8) the activity 
signal was ~130-fold greater than that of the initial, unselected library (R0), and ~40-fold greater 
than that of wt srtA (Figure 2-10A, B). These observations suggested that the system had 
evolved sortase variants with substantially improved activities.  
 
Characterization of Evolved Sortase Mutants 
 We used the above assay to evaluate the activity of individual clones from R4 and R8 
together with wt srtA and the inactive C184A mutant (Figure 2-10B). All tested mutants from R4 
Figure 2-11. Mutations in evolved sortases.  
(A) Highly enriched mutations are highlighted in black; other mutations are shown in blue. (B) Mapping 
evolved mutations on the solution structure of wild-type S. aureus sortase A covalently bound to its Cbz-
LPAT substrate. The calcium ion is shown in blue, the LPAT peptide is colored cyan with red labels, and 
the side chains of amino acids that are mutated are in orange. The N-terminal Cbz group is shown in stick 
form in cyan. 
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exhibited improved activity relative to wild-type, with the two most active mutants, 4.2 and 4.3, 
showing ~20-fold more activity than wt srtA. Mutants isolated from R8 exhibited even greater 
gains in activity, including four mutants that were ≥ 100-fold more active than wild-type srtA 
under the assay conditions (Figure 2-10B). 
 Sequences of evol ved sortase genes revealed the predominance of P94S or P94R, 
D160N, D165A, and K196T m utations among R8 clones (Figure 2-11A). Of the 16 unique 
sequences   
Table 2-1 Kinetic characterization of mutant sortases.  
Kinetic parameters kcat and Km were obtained from fitting initial reaction rates at 22.5 °C to the 
Michaelis-Menten equation. Errors represent the standard deviation of three independent 
experiments. 
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we isolated from R8, nine contained all four mutations. Thirteen of the 16 unique sequences 
contained at least three of the mutations, and all sequences contained at least two of the four 
mutations. All of these mutations also appeared in clones isolated from R4, but no clone from R4 
contained more than two of the mutations, suggesting that recombination following R4 enabled 
combinations of mutations that persisted in rounds 4-8. Indeed, the highly enriched tetramutant 
combination appears to have arisen from recombination of two mutations each from clones 4.2 
and 4.3, the two most active mutants isolated from R4. Gene shuffling was therefore an 
important component of th e evolutionary strategy to generate genes encoding the most active 
sortase enzymes tested. 
None of these four mutations have been reported in previous mutational studies studying 
the sortase active site and the molecular basis of LPETG substrate recognition
27,28
. To gain 
insight into how these mutations improve catalysis, we expressed and purified each sortase single 
Figure 2-12 Comparison of the kinetic parameters of four evolved sortases.  
(A) Plots of reaction velocity (turnovers per second) vs. LPETG peptide substrate concentration, with 
[GGG] fixed at 9 mM. (B) Plots of reaction velocity vs. GGG concentration, with [LPETG peptide] 
fixed at 1 mM. Due to its poor kinetics under the assay conditions, the plot for wt srtA is shown in the 
inset. 
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mutant, clones 4.2 and 4.3, and the tetramutant from E. coli, and we measured the saturation 
kinetics of wt srtA and the mutants using an established HPLC as say
29
. The observed kinetic 
parameters for the wild-type enzyme closely match those previously reported
27,29
. Each single 
mutation in is olation contributed a small beneficial effect on turnover (kcat) and more significant 
beneficial effects on LPETG substrate recognition, lowering the Km LPETG up to three-fold (Table 
2-1). The effects of the mutations in combination were largely additive. Compared to wild-type, 
4.2 and 4.3 exhibited a 2.0-2.6 -fold improvement in kcat and a 5-7-fold reduction in Km LPETG, 
resulting in a ~15-fold  enhancement in catalytic efficiency at using the LPETG substrate (Table 
2-1). Combining all four mutations yielded a sortase enzyme with a 140-fold improvement in its 
ability to convert LPETG (kcat/Km LPETG). This large gain in catalytic efficiency is achieved 
primarily through 45-fold improved LPETG recognition accompanied by a 3-fold gain in kcat 
(Table 2-1, Figure 2-12). 
The effects of the individual mutations on LPETG substrate recognition can be 
rationalized in light of the rep orted solution structure of wt S. aureus srtA covalently bound to 
an LPAT peptide substrate
30
. The mutated residues are all located at the surface of the enzyme, 
near the LPAT-binding groove (Figure 2-11B). P94 lies at the N-terminus of helix 1, and K196 
lies at the C-terminus of the β7/β8 loop. Both D160 and D165 lie in the region connecting β6 and 
β7 that participates in LPETG substrate binding. D165 lies at the N-terminus of a 310 helix that is 
formed only upon LPAT binding and makes contacts with the leucine residue of LPAT. The 
localization of the mutations within loops that line the LPAT binding groove suggests that they 
may be improving binding by altering the conformation of these important loops. 
The evolved sortase mutants exhibit decreased GGG substrate binding (Table 2-1, Figure 
2-12). Compared to wild-type, we measured a 30-fold increase in Km GGG for the sortase A 
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tetramutant. P94S and D 165A had larger detrimental effects on Km GGG than D160N and K196T. 
These results are consistent with mapping of the GGG-binding region proposed by NMR amide 
backbone chemical shift data. The chemical shifts of the visible amide hydrogen resonances for 
residues 92-97 and 165 were among the most perturbed upon binding of a Gly3 peptide
30
. Due to 
the absence of a high-resolution structure of the srtA- Gly3 complex at this time, it is difficult to 
rationalize in more detail the basis of altered Km GGG among evolved mutants. 
Figure 2-13 Time course of turnovers by the evolved P94R/D160N/D165A/K190E/K196T sortase. 
 P94R/D160N/D165A/K190E/K196T srtA (914 pM) was incubated with 9 mM GGG and 1 mM Abz-
LPETGK(Dnp) substrate in 500 μL of reaction buffer.  At 5-minute intervals, 40-μL aliquots were 
removed, quenched, and analyzed by HPLC as described in the Supporting Information.  Each μM of 
product generated over the course of this experiment corresponds to approximately 1,092 turnover 
events.  Averaged data and standard deviation from triplicate experiments are shown as open squares and 
bars, respectively.  Fit lines were generated by Mathematica according to the integrated Michaelis 
Menten equation, [Product] = [Substrate]0 - Km ProductLog[ Exp[ ([Substrate]0 – 
kcat*time*[Enzyme])/Km ] * [Substrate]0/Km ], where [Substrate]0 = 1 mM and [Enzyme]=914 pM.  The 
expected product concentration from previously determined kinetic parameters is shown (black line) 
while a fit line to the data is shown (dashed).  These data show an r2 correlation of 0.983 with kinetic 
parameters kcat = 4.7 ± 0.6 s
-1 and Km LPETG = 245 ± 5 μM, compared with the parameters of kcat = 5.4 ± 
0.4 s-1 and Km LPETG = 230 ± 20 µM determined by endpoint analysis (Table 1, Figures S11, S12).  The 
difference in observed kcat is not statistically significant by Students’ t test to p>0.95. 
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To recover some of the ability to bind the GGG substrate, we reverted A165 of the 
tetramutant back to the original  aspartic acid residue found in wild-type because our results 
indicated that the D165A mutation was most detrimental for GGG recognition. Compared to the 
tetramutant, this P94S/D160N/K196T triple mutant exhibited a 2.6-fold improvement in Km GGG, 
accompanied by a three-fold increase in Km LPETG and no change in kcat (Table 2-1, Figure 2-12). 
We also subjected the R8 yeast pool to one additional round of screening (R9), immobilizing 
LPETGG on the cell surface before reaction with 100 nM GGGYK-biotin. The 
P94S/D160N/K196T reversion mutant was recovered in two out of the 24 sequenced clones from 
R9, but a different triple mutant (P94S/D160N/D165A) dominated the R9 population after 
screening, representing 14/24 sequenced clones.  Compared to the tetramutant, the Km GGG of this 
mutant improved by 2.7-fold, whereas the kcat and KM LPETG were not altered by more than a 
factor of 3-fold (Table 2-1).  
We also performed muta genesis and enrichment to identify additional mutations that 
improve GGG recognition in the tetramutant context. We combined four R8 clones as templates 
for additional diversification by PCR, and subjected the resulting yeast library (R8mut) to two 
rounds of screening, immobilizing LPETGG on the cell surface before reaction with 100-1000 
nM GGGYK-biotin. After two rounds of enrichment, the K190E mutation originally observed in 
clone 4.2 was found in 56% of the unique sequenced clones in R10mut, and 33% of the clones 
possessed P94R in place of P94S. The other three mutations of the tetramutant motif were found 
intact in 89% of the unique R10mut clones. We constructed the 
P94R/D160N/D165A/K190E/K196T pentamutant and assayed its activity. Compared to the 
tetramutant, the Km GGG of this mutant improved by 1.8-fold, whereas the kcat and KM LPETG were 
not altered by more than a factor of 1.3-fold. Compared with wt srtA, this pentamutant has a 120-
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fold higher kcat/Km LPETG an d a 20-fold higher Km GGG (Table 2-1, Figure 2-12). To validate our 
enzyme kinetics measurements, we followed product formation over one hour and observed 
turnover numbers of greater than 10,000 per hour.  The resulting data (Figure 2-13) yielded kcat 
and KM LPETG values that closely agr ee with our kinetics measurements (Table 2-1). Collectively, 
these results indicate that relatives of the evolved tetramutant can exhibit partially restored GGG 
binding and therefore provide alternative enzymes for applications in which the GGG-linked 
substrate is available only in limited quantities. 
 
Figure 2-14 Cell-surface labeling with wild-type and mutant sortases.  
Live HeLa cells expressing human CD154 conjugated at its extracellular C-terminus to LPETG were 
incubated with 1 mM GGGYK-biotin and no sortase A (srtA), 100 µM wild-type srtA, or 100 μM 
P94S/D160N/K196T srtA. The cells were stained with AlexaFluor-conjugated streptavidin. (A) Flow 
cytometry analysis comparing cell labeling with wild-type sortase (blue) and the mutant sortase (red). 
Negative control reactions omitting sortase (black) or LPETG (green) are shown. (B) Live-cell confocal 
fluorescence microscopy images of cells. The YFP (transfection marker) and Alexa (cell labeling) 
channels are shown. 
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Cell-Surface Labeling With an Evolved Sortase 
The improved activities of the evolved sortase enzymes may enhance their utility in 
bioconjugation applicati ons such as the site-specific labeling of LPETG-tagged proteins 
expressed on the surface of living cells. In these a pplications, the effective concentration of the 
LPETG peptide is typically limit ed to micromolar or lower levels by endogenous expression 
levels, and therefore the high KM LPETG of wt srtA (KM LPETG = 7.6 mM, Table 1) necessitates the 
use of a large excess of coupling partner and enzyme to drive the reaction to a reasonable yield. 
As it is typically straightforward to synthesize milligram quantities of short oligoglycine-linked 
probes using solid-phase peptide chemistry, we hypothesized that the much higher kcat/Km LPETG 
Figure 2-15 Cell-surface labeling with four evolved sortases.  
Live HeLa cells expressing human CD154 conjugated at its extracellular C-terminus to LPETG 
were incubated with 0.5 mM GGGYK-biotin and no sortase A (no srtA) or 100 µM of the 
mutant sortase A shown in the legend. The cells were stained with AlexaFluor594-conjugated 
streptavidin (SA-Alexa594) before flow cytometry analysis. Negative control reactions omitting 
sortase (green) or LPETG (gray) are shown. Untreated cells stained with SA-594 (cyan) are also 
shown. 
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of the evolved sortase enzymes might enable them to mediate cell-surfacing reactions that would 
be inefficient using the wild-type enzyme. 
We expressed human CD154 tagged with the LPETG sequence at its C-terminus on the 
surface of HeLa cells an d compared the labeling of the live cells with GGGYK-biotin using wt 
srtA and the evolved P94S/D160N/K196T mutant. After staining with a streptavidin-
AlexaFluor594 conjugate, flow cytometry analysis revealed that the evolved sortase yielded ≥ 
30-fold higher median fluorescence than the wild-type enzyme (Figure 2-14A). Although we 
used condition s similar to those used to label HEK293 cells using wt srtA for fluorescence 
microscopy
5
, over four independent replicates, the wild-type enzyme did not result in 
fluorescence more than 2.8-fold higher than the background fluorescence of cells incubated in 
the absence of enzyme (Figure 2-14A). Consistent with the flow cytometry data, live-cell 
fluorescence microscopy confirmed very weak labeling by wt srtA and much more efficient 
labeling by the evolved sortase mutant (Figure 2-14B). Cells expressing CD154 without the 
LPETG tag were not labeled to a significant extent by the evolved sortase, indicating that the 
site-specificity of the enzyme has not been significantly compromised. Under the conditions 
tested, the evolved sortase triple, tetra-, and pentamutants all exhibit comparable and efficient 
cell-surface labeling, despite their differences in Km GGG (Figure 2-15). Collectively, our results 
suggest that the sortase variants evolved using the enzyme evolution system developed in this 
work are substantially more effective than the wild-type enzyme at labeling LPETG-tagged 
proteins on the surface of live mammalian cells.  
Discussion 
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 We integrated yeast display, Sfp-catalyzed bioconjugation, and cell sorting into a general 
directed evolution strategy for enzymes that catalyze bond-forming reactions. We validated the 
system through model selections enriching for S. aureus sortase A-catalyzed transpeptidation 
activity, attaining enrichment factors greater than 6,000 after a single round of sorting. We 
applied this system to evolve sortase A for improved catalytic activity. After eight rounds of 
sorting with one intermediate gene shuffling step, we isolated variants of sortase A that 
contained four mutations that together resulted in a 140-fold increase in LPETG-coupling 
activity compared with the wild-type enzyme. An evolved sortase enabled much more efficient 
labeling of LPETG-tagged human CD154 expressed on the surface of HeLa cells compared with 
wild-type sortase. 
The kinetic properties of the mutant sortases accurately reflect our screening strategy. 
The 50-fold decrease in Km LPETG of the tetramutant compared to wild-type is consistent with 
lowering the concentration of free biotinylated LPETG peptide during the reaction in successive 
rounds. Meanwhile, this screening format ensured that a high effective molarity of GGG was 
presented to each enzyme candidate over eight rounds of enrichment, which we estimated to be 
~950 μM (Figure 2-16). It is therefore unsurprising that GGG recognition among evolved 
sortases drifted during evolution. Likewise, the three-fold increase in kcat of the tetramutant 
compared to that of the wild-type enzyme may have resulted from screening pressures arising 
from shortening the reaction time in later rounds. Larger increases in kcat may require modified 
selection or screening strategies that explicitly couple survival with multiple turnover kinetics, 
perhaps by integrating our system with in vitro compartmentalization. 
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Despite the widespread use of yeast display in the evolution of binding interactions
19
, to 
the best of our knowledge, sortase A is only the third enzyme to be evolved using yeast display, 
in addition to horseradish peroxidase
31,32
 and an esterase catalytic antibody
33
. Our results 
highlight the attractive features of yeast display that offer significant advantages for enzyme 
evolution, including quality control mechanisms within the secretory pathway that ensure display 
of properly folded proteins and compatibility with FACS
19
. For these reasons, we used yeast as 
the vehicle for display instead of an M13 phage simultaneously displaying an Sfp peptide 
substrate and an enzyme library
34
. As the method developed here does not rely on any particular 
screenable or selectable property of the substrates or product, it is in principle compatible with 
any bond-forming enzyme that can be expressed in yeast, including glycosylated proteins that are 
likely incompatible with phage and mRNA display, provided that linkage of the substrates to 
CoA and to the affinity handle is possible and tolerated by the enzyme or its evolved variants. In 
Figure 2-16 Cell-surface reaction time courses to estimate substrate effective molarity.  
Yeast displaying clones 4.2 and 4.3 were first labeled with GGGK-CoA and then reacted with 1 μM 
biotin-LPETGG as described. Representative reaction progress curves for clone 4.2 (A) and 4.3 (B). 
The data was fit according to the equation described in the Supporting Information. In this case, the 4.2 
data show an r2 correlation of 0.999 with a cell surface GGG effective molarity estimate of 1.007 mM 
and a theta estimate of 156 s, while the 4.3 data show an r2 correlation of 0.982 with a GGG effective 
molarity estimate of 0.967 mM and a theta estimate of 0 s . 
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cases in which the enzyme accepts only one of these modifications, product-specific antibodies 
in principle could be used to detect bond formation. Furthermore, we note that integrating our 
yeast display system with the multicolor capabilities of FACS should enable the evolution of 
enzyme substrate specificity.  
 Beyond improving existing activities of natural proteins for research, industrial, and 
medicinal use, we speculate that the enzyme evolution strategy presented here will be valuable in 
the engineering of artificial proteins with new, tailor-made catalytic activities. The reactions 
catalyzed by natural enzymes are only a small subset of the diverse array of reactions known in 
organic chemistry, and a promising route to generating artificial enzymes is the computational 
design of a protein catalyst with arbitrary activity followed by optimization of its catalytic 
activity through directed evolution. Indeed, recent advances in computational protein design 
have created de novo catalysts for the retroaldol
35
, Kemp elimination
36
, and Diels-Alder 
reactions
37
, and these successes demonstrate the feasibility of designing weakly active proteins 
that are ideal starting points for directed evolution. The integration of computational design and a 
general enzyme evolution scheme such as the one presented here represents a promising strategy 
for creating highly active proteins with tailor-made catalytic activities. 
 
Materials and Methods 
Sortase evolution. A library of 7.8107 mutant sortase genes containing an average of 
2.0 amino acid changes per gene was introduced into yeast cells using gap repair homologous 
recombination (see the Supporting Information for details on library construction). In Round 1, 
6108 sortase library-expressing cells were conjugated to GGGK-CoA, incubated with 100 μM 
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biotin-LPETGS for 60 minutes, and stained with streptavidin-PE and an AlexaFluor488-
conjugated anti-HA antibody (Invitrogen). The top 1.4% of the PE/AlexaFluor488 double-
positive population were isolated and grown to saturation. At least a ten-fold excess of cells 
relative to the number of cells recovered from sorting were removed, pelleted, and induced to 
display enzymes at the cell surface with galactose before entering the subsequent round of 
sorting. See Figure S6 for details on screening stringency. Following round 4, the surviving 
sortase genes were amplified by PCR and shuffled using the NeXT method
26
 (see Supporting 
Information for details). The diversified gene library was introduced into yeast to generate a 
library of 6.9107 transformants (see Supporting Information for details). Four additional rounds 
of enrichment were performed with GGG immobilized on the surface and biotinylated LPETG 
peptide provided exogenously. For rounds 9, 9mut, and 10mut, the cells from the previous round 
were modified with CoA-LPETGG in TBS-B with 5 mM MgCl2 and 5 mM CaCl2 for 30 minutes 
to facilitate formation of the acyl-enzyme intermediate, before washing and initiating the 
reaction with 0.1-1.0 µM GGGYK-biotin. 
Mammalian cell labeling. HeLa cells were cultured at 37 °C in DMEM supplemented 
with 10% fetal bovine serum and 1% penicillin-streptomycin under an atmosphere containing 
5% CO2. The cells were transfected with a 9:1 ratio of plasmid pCDNA3-CD154-
LPETG:cytoplasmic YFP expression plasmid (as a transfection marker). After 24 hours, the 
transfected cells were trypsinized, re-plated onto glass coverslips, and incubated overnight at 37 
°C. Each coverslip was washed twice with Hank’s balanced salt solution (HBSS) and immersed 
into HBSS supplemented with 1 mM GGGYK-biotin, 5 mM CaCl2, and 100 μM enzyme. After 5 
to 10 minutes, the coverslips were washed twice with PBS supplemented with 1% bovine serum 
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albumin (BSA), 1 mM unmodified GGG, and 5 mM MgSO4 before immersion into a solution of 
streptavidin-AlexaFluor594 (1:200, Invitrogen) in PBS with 1% BSA and 5 mM MgSO4. For 
flow cytometry analysis, the coverslips were washed twice with PBS before incubation in PBS 
on ice for 30 minutes. Cells were resuspended and analyzed using a BD Fortessa flow cytometer. 
The AlexaFluor594 fluorescence of the top 16-25% most YFP-positive cells was recorded. For 
imaging, the coverslips were washed twice with PBS containing 5 mM MgSO4 before analysis 
on a Perkin Elmer spinning disk confocal microscope (Harvard Center for Biological Imaging). 
Images were recorded using the DIC, YFP, and Alexa channels. 
Methods for Sortase Reactions on Yeast Cells and Model Screens. 
Sortase Reactions on Yeast with Biotinylated GGG Peptide.  Saccharomyces 
cerevisiae cells displaying Staphylococcus aureus sortase A and the S6 peptide (see below for 
details on induction of yeast display) were resuspended to a cell density of 2.5×10
8
 cells/mL in 
Tris-buffered saline (pH 7.5) with 1 mg/mL bovine serum albumin (TBS-B) and 5 mM MgCl2 
and incubated with 6 μM Sfp and 5 μM CoA-LPETGG (see below for synthesis details) for 15 
minutes. Cells were pelleted and washed with TBS-B before resuspension to a cell density of 
3×10
6 
to 1×10
7 
cells/mL in TBS-B with 5 mM CaCl2 and 10 nM to 100 μM GGGYK-biotin 
peptide. After 15 to 60 minutes, the reactions were stopped by pelleting the cells and washing 
with ice-cold phosphate-buffered saline with 1 mg/mL bovine serum albumin (PBS-B). The cells 
were washed with ice-cold PBS-B containing 500 M AAEK2 (Astatech), an inhibitor of sortase 
enzymes
38
, and 100 M unmodified GGG (Sigma) before incubation with streptavidin-
phycoerythrin (streptavidin-PE) (Fluka) and AlexaFluor488-conjugated anti-hemagglutinin 
antibody (Invitrogen) to detect the extent of the sortase-catalyzed reaction and the enzyme 
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display level, respectively. Cells were washed once more with PBS-B before flow cytometry 
analysis or FACS. 
Sortase Reactions on Yeast with Biotinylated LPETG Peptide. Yeast cells were 
conjugated to GGGK-CoA (see below for synthesis details) and reacted with the biotinylated 
LPETG peptide as described above. After stopping the reaction by centrifuging and washing, the 
cells were resuspended in TBS-B containing 5 μM TEV S219V protease39 and incubated for 15-
30 minutes to remove the background signal from the formation of any covalent acyl biotin-
LPETG-enzyme intermediate. After washing with cold PBS-B, the cells were stained with 
fluorophore-conjugated proteins as described above. 
Model Screens. Yeast displaying wild-type sortase or the inactive C184A mutant were 
mixed in ratios of 1:1000 and 1:100 wt:C184A and treated as described above. After incubation 
with fluorophore-conjugated proteins, 10
7
 cells from each mixture were sorted in a MoFlo cell 
sorter (DakoCytomation). The top 0.06% and top 0.7% of the PE/AlexaFluor488 double positive 
population for the 1:1000 and 1:100 experiments, respectively, were collected. Collected cells 
were cultured until saturation in growth media (see below) with 50 μg/mL carbenicillin, 25 
μg/mL kanamycin, and 50 μg/mL streptomycin. Plasmid DNA was harvested using the 
Zymoprep kit (Zymo Research), and the recovered sortase genes were amplified using the 
primers 5’-CCCATAAACACACAGTATGTT and 5’-AATTGAAATATGGCAGGCAGC and 
digested with HindIII to determine the relative recovery of wild-type and C184A genes.  
Sortase Assay Methods. 
Flow Cytometry Activity Assay For Yeast Pools or Individual Yeast Clones.  A total 
of 1.25107 yeast cells were resuspended in 50 L of TBS-B containing 5 μM TEV S219V 
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protease, 5 mM MgCl2, and 5 mM CaCl2. After incubation for 30 minutes at room temperature, 
the CoA-LPETGG and GGGYK-biotin peptides were added to the cell suspension to final 
concentrations of 5 M and 25 M, respectively. The cells were incubated at room temperature 
for an additional 30 minutes before Sfp was added to a final concentration of 6 M. The cells 
were incubated at room temperature for 7 minutes, pelleted by centrifugation, and washed with 
ice-cold PBS-B. The cells were stained with fluorophore-conjugated proteins as described above, 
washed, and analyzed by flow cytometry. 
In Vitro Sortase Kinetics Assays.  See below for details on sortase expression and 
purification, and on the synthesis of Abz-LPETGK(Dnp)-CONH2. Assays to determine kcat and 
Km LPETG were performed in 300 mM Tris pH 7.5, 150 mM NaCl, 5 mM CaCl2, 5% v/v DMSO, 
and 9 mM Gly-Gly-Gly-COOH (GGG). The concentration of the LPETG peptide substrate 
ranged from 12.5 μM to 10 mM, and enzyme concentrations ranged from 25 nM to 1000 nM. 
Assays for determination of Km GGG were performed under the same conditions, except the 
LPETG peptide concentration was fixed at 1 mM, the enzyme concentration was fixed at 41.5 
nM, and the concentration of GGG was varied from 33 μM to 30 mM, depending on the enzyme. 
Reactions were initiated with the addition of enzyme and incubated at 22.5 °C for 3 to 20 
minutes before quenching with 0.5 volumes of 1 M HCl. Five to ten nmol of peptide from the 
quenched reactions were injected onto an analytical reverse-phase Eclipse XDB-C18 HPLC 
column (4.6150 mm, 5 μm, Agilent Technologies) and chromatographed using a gradient of 10 
to 65% acetonitrile with 0.1% TFA in 0.1% aqueous TFA over 13 minutes. Retention times 
under these conditions for the Abz-LPETGK(Dnp)-CONH2 substrate, the released GKDnp 
peptide, and the Abz-LPETGGG-COOH product were 12.8, 10.4, and 9.1 min, respectively. To 
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calculate the percent conversion, the ratio of the integrated areas of the Abz-LPETGGG-COOH 
and Abz-LPETGK(Dnp)-CONH2 peptide Abs220 peaks was compared to a standard curve 
generated by mixing the product and starting peptide in known ratios. To determine kcat and Km, 
reaction rates were fit to the Michaelis-Menten equation using OriginPro 7.0 software.   All 
kinetics values reported represent the average of at least three measurements. 
Substrate Synthesis Methods.   
Biotin-LC-LELPETGG-CONH2, Fmoc-GGGK-CONH2, and NH2-YLELPETGG-
CONH2 were purchased from Genscript and used without further purification. NH2-
GGGYK(biotin)-CONH2 was purchased from Genscript and purified using reverse-phase HPLC 
on a C18 column. Biotin-LC-YGLPETGS-CONH2 was purchased from New England Peptide 
and used without further purification. 
Synthesis of GGGK-CoA.  Fmoc-GGGK-CONH2 was dissolved in DMSO to a final 
concentration of 100 mM, and 1.5 equivalents of sulfo-SMCC (Thermo-Fisher) and 2 
equivalents of DIPEA (Sigma) in DMSO were added. The reaction was incubated for 1 hr at 
room temperature, then added to 1.5 equivalents of coenzyme A trilithium hydrate (Sigma) in 
DMSO to a final peptide concentration of 25 mM and mixed at room temperature overnight. If 
appropriate, the Fmoc protecting group was removed with 20% vol/vol piperidine and incubation 
for 20 minutes. The reaction was quenched by the addition of 1 equivalent of TFA, and the 
product was purified on a preparative Kromasil 100-5-C18 column (21.2×250 mm, Peeke 
Scientific) by reverse phase HPLC (flow rate:  9.5 mL/min; gradient: 10% to 70% acetonitrile 
with 0.1% TFA in 0.1% aqueous TFA gradient over 30 minutes; retention time: 17.1 minutes). 
ESI-MS (found): [M-H]
-
 m/z = 1300.1. Calculated for C45H72N14O23P3S
-
: m/z = 1301.4. The 
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concentration of GGGK-CoA peptide was determined from the measured A259 using the known 
molar extinction coefficient of coenzyme A, 15,000 M
-1
 cm
-1 40
. 
Synthesis of CoA-LPETGG.  NH2-YLELPETGG-CONH2 (0.0084 mmol) was 
incubated with sulfo-SMCC (0.021 mmol, 2.5 eq.) in 142 μL of DMSO and 3 μL DIPEA (0.017 
mmol, 2.0 equivalents) for 2 hours at room temperature. The maleimide adduct was purified 
using reverse-phase HPLC on a preparative C18 column (flow rate:  9.5 mL/min; gradient: 10% 
to 60% acetonitrile with 0.1% TFA in 0.1% aqueous TFA over 30 minutes; retention time:  22.0 
minutes). After lyophilization of the collected peak, the white solid was dissolved in 0.1 M 
phosphate buffer pH 7.0 with 45% acetonitrile. Coenzyme A trilithium hydrate (11.2 mg) was 
added, and the reaction was incubated at one hour at room temperature. The desired product was 
obtained after purification on a C18 column (flow rate:  9.5 mL/min flow rate; 0% to 50% 
acetonitrile in 0.1 M triethylammonium acetate over 30 minutes; retention time:  21.9 minutes). 
ESI-MS (found): [M-H]
- 
m/z = 1961.8. Calculated for C77H116N18O34P3S
-
: m/z =1961.7. The 
concentration of CoA-LPETGG peptide was determined as described above for GGGK-CoA. 
 Abz-LPETGK(Dnp)-CONH2 Substrate for HPLC Assays.  This compound was 
synthesized at 200 μmol scale using an Applied Biosystems 433A peptide synthesizer. 200 
μmol-equivalents of NovaPEG Rink Amide resin (EMD biosciences) were loaded onto the 
machine and coupled using 5 equivalents of each Fmoc-protected amino acid building block with 
standard acid labile side-chain protecting groups (Thr(OtBu), Glu(OtBu)) and using Fmoc 
Lysine(Dnp) (Chem-Impex). Terminal coupling with Boc 2-Aminobenzoic Acid (Chem-Impex) 
yielded the fully protected peptide, which was cleaved by three 1-hour treatments with 20 mL of 
95% TFA + 2.5% water + 2.5% triisopropylsilane (Sigma). The cleavage mixtures were pooled 
and concentrated by rotary evaporation, and the peptide was precipitated by the addition of 9 
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volumes of ice-cold diethyl ether. The samples were purified by reverse phase HPLC as 
described above for GGGK-CoA (retention time:  28 minutes), pooled and concentrated by 
lyophilization. The concentration of the peptide was determined by the known molar extinction 
coefficient of the Dnp group, ε355nm = 17,400 M
-1 
cm
-1
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. 
Cloning Methods Including Library Generation. 
Primers Used in the Procedures Below 
prime
r 
sequence 
1F 5’-
TCCAGACTATGCAGGATCTGAGAACTTGTACTTTCAAGGTGCTAGCCAAGCT
AAACCTCA 
1R 5’-CAGAAATAAGCTTTTGTTCGGATCCTTTGACTTCTGTAGCTACAAAG 
2F 5’- CC TA ACACAC GTATGTT 
2R 5’-ACCTTGAAAGTACAAGTTCTCAGATCCTGCATAGTCTGGAACGTCGT 
3F 5’-AAAGATAAACAATTAACATTAATTACTGCTGATGATTACAATGAA 
3R 5’-ATCTCGAGCTATTACAAGTCCTCTTCAGAAATAAGCTTTTGTTCGGA 
4F 5’-GTGGAGGAGGCTCTGGTGGAGGCGGTAGCGGAGGCGGAGGGT 
4R 5’-AGTAATTAATGTTAATTGTTTATCTTT 
5F 5’-TGGGAATTCCATATGCAAGCTAAACCTCAAATTCCG 
5R 5’-TTTTTTCTCGAGTTTGACTTCTGTAGCTACAAAG 
6R 5’-AATTGAAATATGGCAGGCAGC 
7F 5'-CCAGGACCAGCAACAAGYGAACAATTAAATAGA  
8F 5'-ATGACAAGTATAAGAAAYGTTAAGCCAACAGCKGTAGAAGTTCTAGAT 
9F 5’-TTAATTACTTGTGATGGKTACAATGAAAAGACA 
Y = C,T; K=G,T; underlined nucleotides represent mixtures of 70% the indicated nucleotide and 
10% each of the remaining three nucleotides  
 
YIPlac211-GPD-S6-Aga1p and Integration Into the Yeast Genome.  The YIPlac211-
GPD-Avitag-Aga1p plasmid, constructed by ligation of the Avitag-Aga1p gene into YIPlac211 
(ATCC) at BamHI / SacI and ligation of the glyceraldehyde-3-phosphate dehydrogenase (GPD) 
promoter sequence at XbaI / BamHI, served as the starting point. The S6 peptide sequence was 
inserted after the signal sequence and before Ile30 of Aga1p by overlap extension PCR. The 
extended PCR product was digested with BamHI and BsiWI and ligated into similarly digested 
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YIPlac211-GPD-Avitag-Aga1p plasmid, resulting in the yeast integrating plasmid YIPlac211-
GPD-S6-Aga1p.  
To integrate the plasmid into the genome, YIPlac211-GPD-S6-Aga1p was linearized by 
digestion with BsiWI and transformed into S. cerevisiae strain BJ5465 with lithium acetate, 
selecting for transformants harboring the integrated plasmid on solid media lacking uracil. A 
yeast colony with the S6-Aga1p construct correctly inserted was designated ICY200 and displays 
the S6 peptide sequence constitutively on the cell surface as a fusion to the N-terminus of Aga1p.  
pCTCon2CTEV-wt srtA and pCTCon2CTEV-srtA C184A (−HindIII).  The 
pCTCon2CTEV-wt srtA plasmid was constructed inside yeast through a three-part, gap repair 
homologous recombination process
42
.  The pCTCon2B-BirA plasmid, which was constructed 
from pCTCon2 and expresses the Aga2p-linker-HA-E. coli biotin ligase-myc construct, served 
as the starting point. S. aureus genomic DNA was amplified with primers 1F and 1R, and 
pCTCon2B-BirA with primers 2F and 2R. These two products were transformed together with 
PstI / BamHI-digested pCTCon2B-BirA into S. cerevisiae strain ICY200 to yield the 
pCTCon2CTEV-wt srtA plasmid. The cloned sortase A gene lacks the N-terminal 59 amino 
acids, which do not impact catalytic activity
43
, but these amino acids are still included in the 
numbering for the mutations. 
 To introduce the C184A mutation, pCTCon2CTEV-wt srtA was separately amplified 
with primer pairs 3F/3R and 4F/4R, and the two gene fragments were transformed into ICY200 
together with NheI / BamHI-digested pCTCon2CTEV-wt srtA. The HindIII site within the myc 
coding sequence was then removed using an analogous process, allowing the wt and C184A 
plasmids to be distinguished by a HindIII restriction digest. 
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pET29 Sortase Expression Plasmids.  Sortase genes were subcloned into pET29 at 
NdeI and XhoI using the primers 5F and 5R. Plasmids encoding sortase single mutants were 
constructed using the Quikchange method. All expressed sortases lack the N-terminal 59 amino 
acids. 
Sortase A Library R0.  The round zero (R0) sortase A library was cloned into S. 
cerevisiae ICY200 using gap repair homologous recombination. The wild-type sortase A gene, 
lacking the N-terminal 59 amino acids, was mutagenized in PCR reactions containing 5 μM 8-
oxo-2’deoxyguanosine (8-oxo-dGTP), 5 μM 6-(2-deoxy-b-D-ribofuranosyl)-3,4-dihydro-8H-
pyrimido-[4,5-C][1,2]oxazin-7-one (dPTP), 200 μM each dNTP, and 0.4 μM each of primers 1F 
and 1R. Reactions were thermocycled ten times and the mutagenized genes were further 
amplified in PCR reactions without mutagenic dNTP analogs using primers 1F and 3R. Gel-
purified genes and NheI / BamHI-digested pCTCon2CTEV-wt srtA were combined in a 1:3 mass 
ratio, concentrated by ethanol precipitation, and electroporated into competent ICY200 as 
described, resulting in a library of 7.8x10
7
 transformants. A total of ~10
9
 cells from the fully 
grown library culture were pelleted and induced as described below. 
Recombined Sortase A library (R4shuf).  In vitro recombination was performed using 
the NExT procedure
26
. Sortase genes recovered after R4 were amplified with the primers 2F and 
6R in PCR reactions containing 50 μM dUTP, 150 μM dTTP, and 200 μM each of dATP, dCTP, 
and dGTP. After purification by gel extraction, 17 μg of the PCR product was incubated with 7.5 
units of uracil deglycosylase (NEB). Piperidine was added (10% vol/vol) and the reaction was 
heated at 90 °C for 3 min. The resulting gene fragments were purified using the QiaExII kit after 
neutralization of the piperidine with glacial acetic acid.  
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Fragments were assembled in PCR reactions containing 1 μg of fragments using the 
conditions reported by Tawfik
44
 In separate fragment assembly reactions, primers 7F, 8F, and 9F 
were each added to the assembly reaction at 0.5 μM and 1.5 μM to favor the inclusion of P94S, 
D160N, D165A, and D186G— mutations that appeared to improve catalytic efficiency based on 
activity assays of individual clones evolved in R3 and R4. Assembly reactions were purified 
using the Qiaquick kit, re-amplified with the primers 1F and 1R, and purified by gel extraction. 
Eight μg of each assembled gene product (24 μg total) were mixed with 7 μg of NheI / BamHI-
digested pCTCon2CTEV plasmid, concentrated by ethanol precipitation, and electroporated into 
competent ICY200 cells as described above, resulting in a library of 6.9x10
7
 transformants. A 
total of ~10
9
 cells from the fully grown library culture were pelleted and induced as described 
below. 
Sortase Library R8mut.  The R8mut library was cloned into yeast as described above 
for the R0 library, starting with an equimolar mixture of the genes encoding clones 8.3, 8.4, 8.5, 
and 8.9 These clones were chosen because they possessed only one extraneous mutation in 
addition to the tetramutant motif (8.3,8.4,8.9), or because they possessed an altered tetramutant 
core (8.5).  More heavily mutagenized library members (8.11, 8.13) were avoided in order to 
minimize deviation from the tetramutant core of mutations.  The concentrations of dPTP and 8-
oxo-dGTP were each 10 μM. Following electroporation into ICY200 as described above, a 
library of 5x10
7
 transformants was obtained with a bulk mutagenesis rate of 1.5%, corresponding 
with an amino acid mutagenesis rate of 1.1%. 
General Yeast Methods.  Yeast cells were transformed with DNA using the lithium 
acetate method. Plasmid DNA from yeast cultures was harvested using the Zymoprep Yeast 
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Plasmid Minipreparation Kit (Zymo Research) following the manufacturer’s instructions. For 
sequencing, zymoprepped DNA was amplified by transformation into E. coli, or sortase genes 
were amplified by PCR using the primers 2F and 6R. 
S. cerevisiae strain ICY200 was propagated in YPD or growth media consisting of 100 
mM phosphate pH 6.6, 2% (w/v) dextrose, 0.67% yeast nitrogen base (Sigma), 100 μg/mL 
cysteine, 100 μg/mL proline, 30 μg/mL histidine, 30 μg/mL methionine, and complete 
supplement mixture lacking uracil (MP Biomedical). Growth media for ICY200 transformed 
with the pCTCon2CTEV yeast display plasmids was the same, except the complete supplement 
mixture lacked uracil and tryptophan. Induction media was the same as the growth media lacking 
uracil and tryptophan, except the carbon source consisted of 1.8% galactose and 0.2% dextrose. 
For induction of display of sortase enzymes on the cell surface, yeast cells from a fully grown 
culture were pelleted, resuspended in induction media at a density of 7x10
6
 cells/mL, and 
incubated at 20 °C for 18-36 hours. Cells were pelleted and washed with TBS supplemented with 
1 mg/mL BSA (TBS-B) before input into assays. 
Protein Expression and Purification 
Bacterial Expression of Sortases.  E. coli BL21(DE3) transformed with pET29 sortase 
expression plasmids were cultured at 37 °C in LB with 50 μg/mL kanamycin until OD600 = 0.5-
0.8. IPTG was added to a final concentration of 0.4 mM and protein expression was induced for 
three hours at 30 °C. The cells were harvested by centrifugation and resuspended in lysis buffer 
(50 mM Tris pH 8.0, 300 mM NaCl supplemented with 1 mM MgCl2, 2 units/mL DNAseI 
(NEB), 260 nM aprotinin, 1.2 μM leupeptin, and 1 mM PMSF). Cells were lysed by sonication 
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and the clarified supernatant was purified on Ni-NTA agarose following the manufacturer’s 
instructions. Fractions that were >95% purity, as judged by SDS-PAGE, were consolidated and 
dialyzed against Tris-buffered saline (25 mM Tris pH 7.5, 150 mM NaCl). Enzyme 
concentration was calculated from the measured A280 using the published extinction coefficient 
of 17,420 M
-1
 cm
-1 45
.  
Bacterial Expression of Sfp Phosphopantetheinyl Transferase. E. coli BL21(DE3) harboring 
the pET29 expression plasmid for Sfp phosphopantetheinyl transferase (a gift from the 
Christopher T. Walsh lab) were cultured at 37 °C in LB with 50 μg/mL kanamycin until OD600 
~0.6. IPTG was added to a final concentration of 1 mM, and protein expression was induced at 
37 °C for three hours. The cells were harvested by centrifugation and lysed by resuspension in B-
PER (Novagen) containing 260 nM aprotinin, 1.2 μM leupeptin, 2 units/mL DNAseI, and 1 mM 
PMSF. The clarified supernatant was purified on Ni-NTA agarose, and fractions that were >95% 
pure were consolidated and dialyzed against 10 mM Tris pH 7.5 +1 mM EDTA +5% glycerol. 
Enzyme concentration was calculated from the measured A280 using the published extinction 
coefficient of 27,220 M
-1
 cm
-1
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Bacterial Expression of TEV S219V Protease.  E. coli BL21(DE3) harboring the 
pRK793 plasmid for TEV S219V expression and the pRIL plasmid (Addgene) were cultured in 
LB with 50 μg/mL carbenicillin and 30 μg/mL chloramphenicol until OD600 ~0.7. IPTG was 
added to a final concentration of 1 mM, and the cells were induced for three hours at 30 °C. The 
cells were pelleted by centrifugation and lysed by sonication as described above for the sortases. 
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The clarified lysate was purified on Ni-NTA agarose, and fractions that were >95% TEV S219V 
were consolidated and dialyzed against TBS. Enzyme concentration was calculated from the 
measured A280 using the reported extinction coefficient  of 32,290 M
-1
 cm
-1 47
. 
Protein Sequences.  Amino acid changes relative to wild-type S. aureus sortase A are 
underlined. 
Aga2p-srtA C184A (Figure 2-4, Figure 2-10B) 
MQLLRCFSIFSVIASVLAQELTTICEQIPSPTLESTPYSLSTTTILANGKAMQGVFEYYKSV
TFVSNCGSHPSTTSKGSPINTQYVFKDNSSTLQASGGGGSGGGGSGGGGSYPYDVPDYA
GSENLYFQGASQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATPEQLNRGVSFAEENE
SLDDQNISIAGHTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRDVKPTDVE
VLDEQKSKDKQLTLITADDYNEKTGVWEKRKIFVATEVKGSEQKLISEEDL 
Aga2p-Clone 8.3 (Figure 2-10B, Figure 2-11A) 
MQLLRCFSIFSVIASVLAQELTTICEQIPSPTLESTPYSLSTTTILANGKAMQGVFEYYKSV
TFVSNCGSHPSTTSKGSPINTQYVFKDNSSTLQASGGGGSGGGGSGGGGSYPYDVPDYA
GSENLYFQGASQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATSEQLNRGVSFAEENE
SLDDQNISIAGHTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRNVKPTAVE
VLDEQKSKDKQLTLITCDDYNEKTGVWETRKIFVATEVKGSEQKLISEEDL 
Aga2p-Clone 8.4 (Figure 2-10B, Figure 2-11A) 
MQLLRCFSIFSVIASVLAQELTTICEQIPSPTLESTPYSLSTTTILANGKAMQGVFEYYKSV
TFVSNCGSHPSTTSKGSPINTQYVFKDNSSTLQASGGGGSGGGGSGGGGSYPYDVPDYA
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GSENLYFQGASQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATSEQLNRGVSFAEENE
SLDDQNISIAGHTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRNVKPTAVE
VLDEQKSKDKQLTLITCDDYNEETGVWETRKIFVATEVKGSEQKLISEEDL  
Aga2p-Clone 8.9 (Figure 2-10B, Figure 2-11A) 
MQLLRCFSIFSVIASVLAQELTTICEQIPSPTLESTPYSLSTTTILANGKAMQGVFEYYKSV
TFVSNCGSHPSTTSKGSPINTQYVFKDNSSTLQASGGGGSGGGGSGGGGSYPYDVPDYA
GSENLYFQGASQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATSEQLNRGVSFAEENE
SLDDQNISIAGHTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYRMTSIRNVKPTAVE
VLDEQKSKDKQLTLITCDDYNEKTGVWETRKIFVATEVKGSEQKLISEEDL  
Aga2p-Clone 8.13 (Figure 2-10B, Figure 2-11A) 
MQLLRCFSIFSVIASVLAQELTTICEQIPSPTLESTPYSLSTTTILANGKAMQGVFEYYKSV
TFVSNCGSHPSTTSKGSPINTQYVFKDNSSTLQASGGGGSGGGGSGGGGSYPYDVPDYA
GSENLYFQGASQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATSEQLNRGVSFAEGNE
SLDDQNISIAGHTYIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRNVKPTAVE
VLDEQKSKDKQLTLITCDDYNEKTGVWETRKIFVATEVKGSEQKLISEEDL  
wild-type S. aureus sortase A (Figure 2-10B, Figure 2-11A, Table 2-1) 
MQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATPEQLNRGVSFAEENESLDDQNISIAG
HTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRDVKPTDVEVLDEQKGKD
KQLTLITCDDYNEKTGVWEKRKIFVATEVKLEHHHHHH 
srtA P94S (Table 2-1) 
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MQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATSEQLNRGVSFAEENESLDDQNISIAG
HTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRDVKPTDVEVLDEQKGKD
KQLTLITCDDYNEKTGVWEKRKIFVATEVKLEHHHHHH 
srtA D160N (Table 2-1) 
MQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATPEQLNRGVSFAEENESLDDQNISIAG
HTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRNVKPTDVEVLDEQKGKD
KQLTLITCDDYNEKTGVWEKRKIFVATEVKLEHHHHHH 
srtA D165A (Table 2-1) 
MQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATPEQLNRGVSFAEENESLDDQNISIAG
HTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRDVKPTAVEVLDEQKGKD
KQLTLITCDDYNEKTGVWEKRKIFVATEVKLEHHHHHH 
srtA K196T (Table 2-1) 
MQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATPEQLNRGVSFAEENESLDDQNISIAG
HTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRDVKPTDVEVLDEQKGKD
KQLTLITCDDYNEKTGVWETRKIFVATEVKLEHHHHHH 
 
Clone 4.2 (Figure 2-10B, Figure 2-11A, Table 2-1) 
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MQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATPEQLNRGVSFAEENESLDDQNISIAG
HTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRNVKPTDVEVLDEQKGKD
KQLTLITCDDYNEETGVWETRKIFVATEVKLEHHHHHH 
Clone 4.3 (Figure 2-10B, Figure 2-11A, Table 2-1) 
MQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATSEQLNRGVSFAEENESLDDQNISIAG
HTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRDVKPTAVEVLDEQKGKD
KQLTLITCDDYNEKTGVWEKRKIFVATEVKLEHHHHHH 
P94S/D160N/D165A/K196T (Table 2-1) 
MQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATSEQLNRGVSFAEENESLDDQNISIAG
HTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRNVKPTAVEVLDEQKGKD
KQLTLITCDDYNEKTGVWETRKIFVATEVKLEHHHHHH 
P94S/D160N/K196T (Table 2-1, Figure 2-14) 
MQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATSEQLNRGVSFAEENESLDDQNISIAG
HTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRNVKPTDVEVLDEQKGKD
KQLTLITCDDYNEKTGVWETRKIFVATEVKLEHHHHHH 
P94S/D160N/D165A (Table 2-1) 
MQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATSEQLNRGVSFAEENESLDDQNISIAG
HTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRNVKPTAVEVLDEQKGKD
KQLTLITCDDYNEKTGVWEKRKIFVATEVKLEHHHHHH 
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P94R/D160N/D165A/K190E/K196T (Table 2-1) 
MQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATREQLNRGVSFAEENESLDDQNISIAG
HTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRNVKPTAVEVLDEQKGKD
KQLTLITCDDYNEETGVWETRKIFVATEVKLEHHHHHH 
Effective Molarity of Surface-Conjugated Substrate Relative to Yeast-Displayed 
Sortase.  Yeast displaying clones 4.2 and 4.3 were conjugated with GGGK-CoA as described in 
Materials and Methods. The resulting cells were incubated with 1 μM Biotin-LPETGG in TBS 
with 5 mM CaCl2, and aliquots were removed at various time points and immediately diluted 
1:20 into ice-cold PBS containing 6 μM TEV S219V, 5 mM AAEK2 (an inhibitor of S. aureus 
sortase A
38
 ), 1 mM berberine chloride (an inhibitor of S. aureus sortase A
48
) , and 5 mM of non-
biotinylated GGG. After incubation on ice for fifteen minutes, the samples were pelleted and 
resuspended in ice-cold PBS containing 6 μM TEV S219V, 5 mM AAEK2, 5 mM GGG for one 
hour. Following staining of the cells with streptavidin-phycoerythrin (for reaction extent) and 
AlexaFluor488-conjugated anti-hemagglutinin antibody (for display), the mean phycoerythrin 
(PE) fluorescence intensities (PE MFI) of the AlexaFluor488-positive cells were recorded with a 
BD Fortessa flow cytometer. When plotted versus time (t), the PE MFI (for reaction extent) for 
the 488/PE-double positive population of each sample were fit to the Poisson equation 
representing the proportion of sites converted for a reaction operating at constant velocity v, 
f∞(1-e
-v*(t+theta)
)+f0. The scaling factor f∞ is taken to represent the fluorescence intensity of a fully 
labeled cell and is determined by allowing reactions to run for two hours and fixing this as the 
endpoint. The minimum fluorescence intensity for a library member, f0, is fixed from the PE MFI 
of 488-negative cells within the population. The velocity of the reaction, v, and the time 
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correction factor, theta, were both determined by nonlinear regression of the data to the fit curve 
using the program Mathematica. The velocity data were then transformed into estimates for the 
effective molarity of displayed enzymes for [GGG] by the use of the previously determined 
Michaelis-Menten relations for clones 4.2 and 4.3, [GGG] = 
Km,GGG*Km,LPETG*v+Km,GGG*[LPETG]*v/(kcat *[LPETG]-Km,LPETG*v-[LPETG]*v) 
[GGG] estimates were made for two technical replicates each of the 4.2 and 4.3 sortase mutants, 
and the overall estimate of [GGG] was found to be 0.95 ± 0.11 mM. 
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Abstract 
 All medical implants that operate in direct contact with blood, such as vascular grafts, stents, 
and catheters, elicit clot formation with long-term use. Antithrombotic therapies such as Plavix® 
may prolong device durability, but carry significant cost and an attendant risk of bleeding. 
Despite advances in bioengineering and medicine, a universally accepted blood compatible 
material does not exist. This work demonstrates the feasibility of a point-of-care scheme to coat 
sterilized commercial vascular grafts with thrombomodulin (TM), a clot resistant protein that 
was more effective than “state of the art” heparin-coated grafts (Gore® Propaten®) in reducing 
thrombosis in a primate model. Moreover, rapid one-step modification of TM using a mutant 
Sortase A enzyme may be a key step towards the industrial scaling and clinical translation of our 
molecularly engineered films that resist thrombosis. 
Introduction 
 All artificial organ systems and medical devices that operate in direct contact with blood 
elicit activation of coagulation and platelets with long-term use,
1,2
 leading to formation of 
thrombosis or emboli that often necessitates antithrombotic therapies, which carry significant 
cost and an attendant risk of bleeding.
3,4
 None of the existing synthetic arterial substitutes are 
suitable for small-caliber (< 6 mm) revascularization procedures, which are central to the fields 
of cardiac, vascular, and plastic surgery, as well as for the implantation of a variety of artificial 
organs.
5,6
 It is now recognized that the adverse events leading to failure of blood contacting 
devices is largely related to maladaptive biological reactions at the blood-material interface, 
which contributes to a substantial risk of early and late thrombotic occlusion.
1,7,8
 Despite 
advances in tissue engineering that have yielded biomaterials that mimic the bulk properties of 
native blood vessels and promote healing,
9-11
 a generally accepted blood compatible material 
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does not exist.
7
 This work demonstrates the feasibility of a point-of-care scheme to site-
specifically immobilize thrombomodulin (TM) on sterilized commercial vascular grafts, which 
exhibited superior thromboresistance compared with heparin-coated grafts (Gore® Propaten®) 
in a non-human primate model of acute graft thrombosis. Rapid one-step modification of TM 
with synthetic alkylamine derivatives such as azides and PEG using an evolved sortase (eSrtA) 
mutant may enable the industrial scaling of this approach. 
 Surface-induced thrombosis hinges on the generation of thrombin, a central mediator that 
amplifies the intrinsic coagulation cascade, crosslinks fibrin, and activates platelets.
12,13
 First 
demonstrated in 1963,
14
 heparin immobilization has been hypothesized to mimic the 
antithrombin activity of cell surface heparan sulfate proteoglycans (HSPG) expressed by the 
endothelium.
15
 Recent randomized clinical trials show that heparin modified surfaces 
substantially improved the clinical outcomes of expanded poly(tetrafluoroethylene) (ePTFE) 
vascular grafts in lower extremity revascularization. Superior 1-year results have been recently 
reported for heparin-bonded ePTFE (Propaten) when compared to non-coated ePTFE.
16
 
Preliminary analysis of heparin-bonded ePTFE covered stents in the superficial femoral artery 
suggests a similar effect.
17,18
 Attenuation of thrombin production at the blood-contacting 
interface, therefore, may be a critical step in the design of blood-compatible materials that 
improve the clinical performance of blood-contacting implants. 
 The physiological role of heparin, produced primarily by mast cells, in hemostasis remains 
unclear
19
 as the majority of anticoagulantly active HSPG is not in direct contact with flowing 
blood
20
 and knock-out mice lacking the specific pentasaccharide sequence that inhibits thrombin 
do not exhibit a procoagulant phenotype.
21
 In contrast, TM is the major vasculoprotective 
molecule localized on the endothelial cell surface and defects therein increase the risk of 
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thromboembolism, as well as inflammatory disorders.
22
 By forming a stoichiometric 1:1 
complex with thrombin, TM sequesters thrombin’s prothrombotic activity, and simultaneously 
accelerates thrombin’s catalytic activity to generate activated protein C (aPC) by 1000-fold. aPC 
inhibits the upstream proteases necessary for amplifying thrombin production and represents the 
primary physiological mechanism which regulates hemostasis.
23,24
 
 Clinical implementation of strategies reported to date on the immobilization of TM,
24-31
 as 
well as other proteins in therapeutic and diagnostic applications, have been primarily limited by 
two main factors: the inherent reduction in activity associated with schemes that non-specifically 
react with free amino, carboxyl, or thiol motifs contained near the catalytically active site, and 
the necessity for terminal sterilization, which in the medical device industry mainly comprise 
either ethylene oxide (EtO) or radiation that often perturb the chemical structure and activity of 
surface-bound biomolecules.
32-34
 We were first to demonstrate a bioorthogonal strategy to site-
specifically tether recombinant human TM via a single C-terminal azide motif (TM-N3) by 
Staudinger Ligation on the luminal surface of 4 mm i.d. ePTFE grafts that preserved the 
therapeutic activity of TM to catalyze aPC generation.
35
 In principle, immobilization of TM on 
sterilized surfaces with stable anchor sites may provide an alternative to terminal sterilization to 
manufacture an off-the-shelf product. However, the limited yield and scalability of auxotrophic 
incorporation of azido-alanine in TM-N3 as well as the propensity of triphenylphosphines to 
degrade by air oxidation
36
 in our previous report would prohibit the clinical translation of such 
an approach. 
 SrtA is a calcium-dependent cysteine transpeptidase found in Staphylococcus aureus and 
other Gram-positive bacteria that anchors proteins containing a C-terminal LPXTG motif (where 
X denotes any amino acid) by breaking the threonine-glycine bond and forming a new amide 
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bond with oligoglycine-linked molecules.
37-39
 Site-specific SrtA transpeptidation of synthetic 
nucleophiles may be a more efficient alternative to unnatural amino acid approaches
40
 to 
incorporate any of a number of functionalities, such as biotin, fluorophores, and azides, to the 
termini of recombinant proteins in one step.
41,42
 We generated a recombinant human TM 
fragment (Figure 3-1) containing the minimal functional domains for antithrombotic activity
43,44
 
Figure 3-1 SDS-PAGE gel tracking of FLAG-tagged TMLPETG 
(a) SDS-PAGE gel tracking of FLAG-tagged TMLPETG purification by anti-FLAG immunoaffinity 
chromatography. (b) Western blot of purified TMLPETG using an antibody that recognizes TM456.  
Lanes: 1 – MW markers, 2 – TMLPETG. 
 
Figure 3-2 Diagrams of SrtA reactions 
(a) Sortase-catalyzed transpeptidation of biotinylated pentaglycine peptide to the C-terminus of 
thrombomodulin (TM). (b) Chemical structure of the biotinylated pentaglycine peptide (Gly5-biotin). 
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and a C-terminal LPETG se quence (TMLPETG) that facilitated subsequent C-terminal fusion with  
a biotinylated pentaglycine peptide probe (Gly5-biotin) and wild-type (WT) SrtA (Figure 3-2). 
TMLPETG exhibited similar catalytic activity to generate aPC in the presence of thrombin and 
calcium compared with previous batches of TM generated in our lab.
44
 However, high molar 
excess of WT SrtA (> 2 molar equiv) and Gly5-biotin (> 10 molar equiv), as well as long 
reaction times (20 h), were required to drive TMLPETG biotinylation yields (Figure 3-3). Our 
observations are in agreement with other reported SrtA-catalyzed protein labeling applications, 
Figure 3-3 Sortase catalyzed transpeptidation of TMLPETG with biotinylated pentaglycine peptide 
(Gly5-biotin) nucleophiles.   
(a) western blot analysis to detect presence of biotin using streptavidin-AP conjugate. (b) Molar ratios of 
the TMLPETG, WT SrtA, and Gly5-biotin nucleophile as well as reaction times. 
Figure 3-4 Tracking Gel of SrtA Transpeptidation of TMLPETG 
SDS-PAGE gel tracking of wild-type (WT) S. aureus sortase A (SrtA) catalyzed transpeptidation of an 
amine-PEG113 (MW 5kDa) to thrombomodulin containing a C-terminal LPETG peptide motif 
(TMLPETG) for 2 h or 20 h reaction time.  Notations: C – controls with only TMLPETG, M – molecular 
weight markers. 
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which were similarly limited by the low catalytic activity of WT SrtA.
41,42
 In addition, we  
confirmed previous reports showing the suitability of alkylamine nucleophile substrates for 
SrtA
42,45
 by demonstrating WT SrtA-catalyzed PEGylation of TMLPETG in the presence of 100 
molar equiv of 5 kDa NH2-PEG, which achieved ~80% yield after 20 h (Figure 3-4). Despite 
their lower efficiency as nucleophiles, the relative synthetic simplicity of alkylamine compared 
with oligoglycine derivatives may further improve the commercial scalability and scope of 
suitable substrates for SrtA-catalyzed protein labeling.  
Figure 3-5 Reaction scheme for SrtA-catalyzed azidylation and protein immobilization 
 
(a) Covalent site-specific ligation of amine-PEGn-X to thrombomodulin (TM) containing a C-
terminal LPETG peptide motif catalyzed by an evolved S. aureus sortase A mutant (eSrtA), where n 
is the number of PEG repeats and X is a bioorthogonal reactive group such as biotin and azide.  (b) 
Surface reaction scheme to modify the lumen of expanded poly(tetrafluoroethylene) (ePTFE) 
vascular grafts with dibenzocyclooctyne (DIBO) that can be sterilized by ethylene oxide (EtO) prior 
to strain-promoted [3+2] cycloaddition to immobilize azide derivatives such as rhodamine, biotin, 
and TM. 
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 The recent development of a general yeast display system has facilitated directed evolution 
of WT SrtA to generate a SrtA pentamutant (eSrtA), which exhibited 120-fold increase in 
catalytic activity,
46
 and enabled the routine preparation of recombinant proteins that contain a 
single C-terminal α-thioester.47 We hypothesized that eSrtA may facilitate rapid labeling of 
TMLPETG with a single azide motif using the commercially available alkylamine derivative NH2-
Figure 3-6 Optimization of eSrtA/TMLPETG reaction conditions 
(a) SDS-PAGE gel tracking of evolved (eSrtA) or wild-type sortase A (WT SrtA) catalyzed 
transpeptidation of an amine-PEG113 (MW 5kDa) to thrombomodulin (TM) containing a C-terminal 
LPETG peptide motif (TMLPETG) over a 16 h time period.  (b) Western blot comparison of eSrtA-
catalyzed transpeptidation of amine-PEG3-biotin (NH2-PEG3-Bio) and biotinylated pentaglycine peptide 
(NH2-Gly5-Bio) under identical reaction conditions.  (c) Strain-promoted [3+2] cycloaddition of 
dibenzocyclooctyne-biotin (DIBO-Bio) with azide-tagged TM, generated by eSrtA-catalyzed ligation of 
NH2-PEG3-N3 to TMLPETG. 
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PEG3-N3 to generate TM-N3 (Figure 3-5A). As shown in Figure 3-6A, eSrtA dramatically 
improved the PEGylation efficiency of TMLPETG with 100 molar equiv of 5 kDa NH2-PEG probe 
as compared to WT SrtA, achieving nearly 80% yield after 2 h with 0.1 molar equiv eSrtA. This 
rapid one-step reaction may be broadly applied to site-specifically PEGylate LPETG-tagged 
recombinant protein therapeutics, which has been routinely performed to optimize half-life and 
biostability.
48,49
 Notably, the reaction of TMLPETG with 1 or 10 molar equiv 5 kDa NH2-PEG for 
2 h yielded minimal TM-PEG product, and no major TM multimer products formed at these 
conditions (Figure 3-7). These observations indicate minimal non-specific transpeptidation with 
exposed primary amines on TMLPETG despite the enhanced catalytic activity of eSrtA. eSrtA was 
equally efficient in catalyzing the biotinylation of TMLPETG (Figure 3-6B) in the presence of 100 
molar equiv Gly5-biotin and NH2-PEG3-biotin, demonstrating equivalency of alkylamines as 
compared to oligoglycines for eSrtA transpeptidation when reacted in high molar excess. Under 
Figure 3-7 Tracking gel of eSrtA transpeptidation 
SDS-PAGE gel tracking of pentamutant S. aureus sortase A (eSrtA)-catalyzed transpeptidation of 1, 10, 
or 100 molar equiv amine-PEG113 (MW 5kDa) relative to thrombomodulin containing a C-terminal 
LPETG peptide motif (TMLPETG) for 5 min or 2 h reaction time.  Notations: M – molecular weight 
markers. 
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optimal reaction conditions, 0.1 equiv eSrtA and 100-fold molar excess NH2-PEG3-N3 relative to 
TMLPETG yielded a TM-N3 conjugate in 2 h, which exhibited selective reactivity with alkyne 
probes (Figure 3-6C). As the high excess of alkylamine derivatives could be removed or 
recovered by established dialysis methods due to their small molecular weight, and His-tagged 
eSrtA could be efficiently removed by applying the crude reaction mixture onto a metal-affinity 
column (Figure 3-8), commercial scale-up of TM-N3 production by eSrtA transpeptidation 
should be feasible.  
 Optimization of strained alkynes has yielded variants that exhibit substantially higher 
reaction kinetics than Staudinger Ligation, while maintaining bioorthogonality to undergo 
cycloaddition with azide without copper catalysis.
50,51
 Dibenzocyclooctyne (DIBO) has been  
Figure 3-8 Removal of eSrtA by metal affinity pulldown 
SDS-PAGE gel tracking of the removal of His-tagged evolved Sortase A (eSrtA, ~17kD) by metal 
affinity chromatography of the crude reaction mixture following reaction of TMLPETG with NH2-PEG-N3. 
78 
 
among the most well char acterized strained alkynes and has been commercialized for cell 
imaging applications.
52
 We synthesized a DIBO-PEG11-NH2 linker that enabled the activation of 
the luminal surface of 4 mm i.d. ePTFE vascular grafts, as well as solvent-cast polyurethane 
(PU) films, with DIBO anchor groups using an approach reported previously
35
 and outlined in 
Figure 3-5B. Commercial ePTFE gr afts activated with DIBO reacted specifically with Rh-N3, as 
verified visually (Figure 3-9). Significantly, we demonstrated that EtO sterilization of DIBO 
modified surfaces did not impair their capacity to bind azide derivatives. Figure 3-10A shows the 
capacity of DIBO to specifically react with rhodamine azide (Rh-N3) was not diminished 
Figure 3-9 Immobilization of rhodamine azide on DIBO functionalize ePTFE grafts 
Visual assessment of rhodamine azide (Rh-N3) or rhodamine B (Rh) immobilization on DIBO 
functionalized ePTFE grafts, compared with plain ePTFE control. 
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following EtO sterilization of DIBO modified PU films. Quantitative measurement of surface 
biotin density in Figure 3-10B confirmed no significant change in DIBO  
reactivity with azide-PEG3-biotin following EtO sterilization of DIBO modified ePTFE grafts. 
Covalent immobilization of TM-N3 on EtO sterilized ePTFE grafts modified with DIBO 
maintained similar levels of catalytic activity to generate ~15 ng aPC cm
-2
 min
-1
 as TM-N3 
immobilized on non-sterile DIBO modified grafts. Collectively, these results support the 
feasibility of immobilizing TM-N3 on sterilized DIBO-modified surfaces that would be carried 
out in the operating room prior to implantation. Similar point-of-care approaches have been 
described, for example, electrospinning of polymer wraps for autologous vein grafts,
53
 as well as 
endothelial cell seeding of ePTFE grafts
54
 prior to implantation, though these methods may carry 
a higher risk of microbial contamination. 
Figure 3-10 Test immobilization on EtO sterilized films 
(a) UV-vis spectroscopy of rhodamine-azide (Rh-N3) or rhodamine B (Rh) immobilized on ethylene 
oxide (EtO) sterilized and non-sterilized thin polyurethane (PU) films functionalized with 
dibenzocyclooctyne (DIBO).  (b) Surface density of biotin-PEG3-N3 immobilized on EtO sterilized and 
non-sterilized expanded poly(tetrafluoroethylene) (ePTFE) grafts modified with DIBO.  (c) Activated 
protein C (aPC) production by EtO treated and non-treated ePTFE grafts. 
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Due to the lack of clinical data that establish the minimal aPC flux required to reduce risk of 
graft thrombosis, the therapeutic characteristics of TM modified ePTFE grafts was evaluated in 
an animal model. Chronic arteriovenous shunt models in baboons, whose hemostatic systems 
most closely mirror that of man, are routinely used to assess the thrombogenicity of blood 
contacting materials under dynamic flow in vivo.
55-57
  Due to tissue injury at the graft 
Figure 3-11 Baboon shunt model for antithrombotic efficacy testing 
(a) Baboon arteriovenous shunt model to measure deposition of platelets on modified expanded 
poly(tetrafluoroethylene) (ePTFE) grafts in the presence of an upstream prothrombotic Dacron segment.  
(b) Quantity of platelets deposited over a 1 h period on the Dacron segment.  (c) Quantity of platelets 
deposited over a 1 h period on unmodified ePTFE control grafts, heparin modified Propaten grafts, and TM 
modified grafts (* p < 0.05, ** p < 0.01). 
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anastomosis, which results in exposure of highly thrombogenic tissue factor and collagen motifs 
to flowing blood,
13
 we devised a multi-compartment shunt configuration that inserted an 
upstream Dacron graft segment that serves as a thrombogenic stress to test the therapeutic 
activity of aPC generated in a downstream TM modified graft segment (Figure 3-11A).  We 
postulated that the Dacron segment may provide a more clinically relevant test bed by 
reconstituting the in vivo thrombogenic stress exerted on implanted graft materials. 
Thrombogenicity of materials was evaluated by measuring the real-time deposition of radio-
labeled autologous platelets on the luminal surface of unmodified ePTFE, TM modified ePTFE, 
as well as commercial heparin modified ePTFE (Propaten) vascular grafts.   
Dacron was prone to platelet deposition as evident by steady accumulation over a 1 h 
perfusion period (Figure 3-11B), which was similar to previous reports.
58,59
 TM modified ePTFE 
graft segments reduced platelet deposition by ~80% (Figure 3-11C) when compared to 
unmodified grafts (n=5, p < 0.01). The therapeutic efficacy of TM was significantly greater than 
the commercial heparin coating, which resulted in a ~50% reduction in platelet deposition 
relative to unmodified grafts (n=5, p < 0.05). Minimal deposition of platelets on heparin 
modified ePTFE in non-human primates had previously been reported in shunt configurations 
that lacked the upstream Dacron segment,
60
 but our current studies suggest that the antithrombin 
III activity catalyzed by heparin may be overwhelmed in the presence of a high upstream 
thrombogenic source. Given the many factors that dictate the durability of an arterial substitute, 
the benefit afforded by TM immobilization will need to be evaluated in long-term surgically 
implanted bypass configurations in vivo.
13
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In summary, we have demonstrated the feasibility of covalently immobilizing TM-N3 on EtO 
sterilized ePTFE grafts as a point-of-care delivery scheme, which may be a key step in the 
clinical translation of biologically active films for permanent implants as a sterile off-the-shelf 
product. Significantly, we demonstrated the superior blood-contacting properties of TM-
modified vascular grafts as compared to current commercial heparin modified grafts in a primate 
model of acute graft thrombosis. Moreover, we have optimized the scalability of producing TM-
N3 by rapid one-step eSrtA transpeptidation of alkylamine azide, and demonstrated the suitability 
of this approach to site-specifically PEGylate or biotinylate TM. Based on growing reports to 
date on the application of WT SrtA, the enhanced reactivty of eSrtA may be a key enabling step 
in the industrial scaling of these strategies.  
Materials and Methods 
  All reagents were purchased from Aldrich, St Louis and used without further purification 
unless otherwise noted. Expression and purification of recombinant TMLPETG and sortases, as 
well as solution phase sortase transpeptidation reactions are detailed in the supplementary 
information section. Gly5-biotin was obtained from Genscript, Piscataway and used without 
further purification. 
 Synthesis of DIBO-PEG11-NH2.  The activated DIBO was synthesized according to a 
previously published protocol.
52
 DIBO-PEG11-NH2 was synthesized by reaction between the 
activated DIBO and t-Boc-N-amido-dPEG11-amine (Quanta BioDesign, Powell) followed by 
TFA deprotection, as detailed previously.
61
 
 Modification of ePTFE Grafts. 5% w/v Elasthane 80A (Polymer Tech, Berkeley) in N,N-
dimethylformamide (DMF) was extruded through 4 mm i.d. ePTFE thin wall vascular grafts 
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(Bard, Tempe) and dried under vacuum at 60°C for 20 min. Additional PU was deposited in 
multiple flow-through/drying cycles over the base layer, and dried overnight under vacuum at 
60 °C. PU coated grafts were inserted into tubular rotary reactors, as described previously for 
surface reactions.
35
 Grafts were first reacted with HDI (16% v/v) and TEA (4% v/v) in toluene at 
50 °C for 1 h and rinsed in toluene for 6 h. Isocyanate activated grafts were reacted with DIBO-
PEG11-NH2 linker (5 mg/mL) and DMSO (1% v/v) in toluene at 40 °C overnight, rinsed with 
toluene for 6 h, and dried under vacuum at 25 °C overnight. Standard EtO sterilization was 
carried out at the Beth Israel Deaconess Medical Center Central Processing (Boston MA). DIBO 
activated grafts were reacted with 1 mg/mL tetramethylrhodamine-5-carbonyl azide (Invitrogen, 
Carlsbad) in 1:4 tert-butanol/TBS at 37 °C for 24 h followed by rinsing in methanol for 2 days, 1 
mM biotin-PEG3-N3 (Pierce, Rockford) in TBS at 37 °C for 24 h followed by rinsing in TBS for 
24 h, or 20 µM TM-N3 in Tris buffered saline (TBS, 20mM Tris, 100mM NaCl, pH 7.5) at 37 °C 
for 24 h and rinsed with TBS for 24 h. Grafts coated with PU and activated with DIBO were 
reacted with rhodamine B or TMLPETG as controls. 
Modification of polyurethane films. Thin clear PU films were solvent cast by drying 12.5% 
w/v PU in DMF for 24 h at 60 °C under vacuum. Films were subjected to isocyanate, DIBO, and 
rhodamine reactions in a glass vial using identical conditions as graft substrates, and 
characterized by UV-Vis spectroscopy (Cary 50 Bio UV-visible spectrophotometer, Varian). 
TM graft cofactor activity assay. A 4 mm graft segment was incubated in 200 µL of 0.2 
µM human protein C (Calbiochem, Gibbstown), 5 mM calcium chloride, and 2 nM human α-
thrombin (Haematologic Technologies, Essex Junction) in Tris buffer (20 mM Tris, 100 mM 
NaCl, pH 7.5) with 0.1% bovine serum albumin (BSA) at 37 °C for 1 h, and quenched with 2 
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IU/mL human anti-thrombin III (American Diagnostica, Stamford) for 5 min. The generation of 
aPC was quantified using 0.2 mM of an enzymatically digestible chromogenic substrate, 
Spectrozyme PCa (American Diagnostica).   
Determination of biotin surface density with streptavidin-HRP probe:  All assay reactions 
were run in a 96-well plate, per manufacturer’s instructions (Pierce). Moles of biotin motifs 
bound to graft samples were determined using a standard curve generated by known 
concentrations of streptavidin-HRP incubated with TMB substrate. At the end of each assay, 
graft segments were flattened between glass slides and scanned at 600 dpi using a HP ScanJet 
5370C scanner and the reactive area of each test sample was measured using ImageJ software. 
 In vivo baboon arteriovenous shunt model.  Chronic exteriorized Silastic tubings were 
implanted in male baboons, as described previously.
62,63
 All studies were approved by the 
Institutional Animal Care and Use Committee at Oregon Health and Science University.  Mean 
blood flow rate through the shunt was measured continuously using a Doppler ultrasonic flow 
meter and held constant by an external screw clamp at 100 mL/min.  Autologous platelets were 
radiolabeled one day prior to shunt study with Indium-111 oxine and re-injected into the baboon. 
Platelet deposition in the individual compartments of the shunt assembly was measured over a 
60-minute perfusion period using a high sensitivity 99Tc collimator and scintillation camera (GE 
400T, General Electric) imaging of the 172 keV 
111
In photon peak at 5-min intervals. 
Thrombogenic devices were assembled and inserted into shunts, as detailed previously.
35
 
 Statistical Analysis.  Two-tailed student’s t-test assuming unequal variances was used to test 
for statistical significance between the means of two groups. 
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 Generation of TMLPETG  The minimal fragment of human thrombomodulin, epidermal 
growth factor-like domains 4 – 6 (TM456) was cloned into the Sigma pFLAG ATS expression 
vector. Amino acid changes relative to the native TM456 sequence are underlined: 
 TMLPETG (15.2 kDa): 
MKKTAIAIAVALAGFATVAQADYKDDDDKVKLVEPVDPCFRANCEYQCQPLNQTS
YLCVCAEGFAPIPHEPHRCQLFCNQTACPADCDPNTQASCECPEGYILDDGFICTDID
ECENGGFCSGVCHNLPGTFECICGPDSALAGQIGTDCGGGGSGGGGSLPETGG  
 Note that highlighted in blue and underlined is the OmpA tag that facilitates transport of 
TMLPETG to the periplasmic space of E coli to optimize folding, this sequence is cleaved in final 
mature TMLPETG. The FLAG peptide sequence is DYKDDDDK at the N-terminus.  It has been 
previously demonstrated that the conversion of the internal methionine residue to leucine 
maximizes the stability of TM. A second mutation was made to convert the internal RH 
sequence, which is an active trypsin cleavage site, to GQ. The additional sequence at the C-
terminus includes a GGGGSGGGGS spacer and the LPETG sortase recognition motif.  An extra 
glycine was added at the C-terminus as this was previously demonstrated to maximize sortase 
activity. 
 Following transformation of chemically competent cells, a fresh LB agar plate was streaked 
with methionine auxotrophic cells containing the appropriate TM vector and incubated at 37 ºC 
overnight.  A single cell colony was then inoculated into 50 mL of Novagen media supplemented 
with 0.4 % glucose and 50 μg/mL ampicillin and cultured at 37 ºC, 225 RPM, for 16 h.  A total 
of 25 mL of fully grown starter culture (OD600 = 1.20) was added per 500 mL of Novagen 
media supplemented with 0.4 % glucose and 50 μg/mL ampicillin, and cultured at 37 ºC, 225 
RPM. Upon cell growth to OD600 = ~0.9, IPTG was added at a final concentration of 1 mM to 
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induce TMLPETG expression, and the culture was incubated for an additional 4 h at 37 ºC, 225 
RPM. Cell cultures were centrifuged at 4,000x RCF at 4 ºC for 10 minutes and stored at 4 ºC. 
Standard osmotic shock protocol was performed on stored cell pellets to extract the crude 
periplasmic proteins. Cell pellets were first warmed to room temperature and re-suspended in 40 
ml/g cells of 0.5 M sucrose, 0.03 M Tris-HCl (pH 8.0) at a final pH of 8.0 per gram of cells. 
Suspended cells were evenly distributed into round bottom centrifuge tubes (60 mL per tube). A 
total of 120 µL of 500 mM sucrose was added to each tube to achieve final 1 mM EDTA 
concentration and incubate with gentle shaking for 10 minutes at RT. The cell suspension was 
centrifuged at 3,500x g for 10 min at 10 °C and the supernatant decanted.  The cell pellet was 
rapidly resuspended in 25 mL/g cell pellet ice-cold, distilled water (40 mL per tube is sufficient) 
for 10 minutes and the cell suspension centrifuged at 3,500x RCF for 10 min at 4 °C. A total of 
35 mL of supernatant was removed from each tube and transferred to clean round bottom 
centrifuge tubes. These were clarified by further centrifugation at 25,000x RCF for 25 min at 4 
°C and sterilized using a 0.22 µm filtration system. Anti-FLAG immunoaffinity chromatography 
(Sigma) was performed on the clarified supernatant per manufacturer’s instructions. SDS-PAGE 
analysis and total protein quantification were performed using standard Bradford assay (Bio-
Rad) protocols from the manufacturer.  
 Bacterial Expression of Evolved Sortase and Wild-type Sortase. The amino acid sequence 
of the wild-type sortase and evolved sortase is provided below: 
 Wild-type sortase with N-terminal His-tag (19.5 kDa): 
MASSHHHHHHDYDIPTTENLYFQGSQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPA
TPEQLNRGVSFAEENESLDDQNISIAGHTFIDRPNYQFTNLKAAKKGSMVYFKVGNE
87 
 
TRKYKMTSIRDVKPTDVGVLDEQKGKDKQLTLITCDDYNEKTGVWEKRKIFVATEV
K 
Evolved sortase with C-terminal His-tag (17.9 kDa) and mutations underlined: 
MQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATREQLNRGVSFAEENESLDDQNIS
IAGHTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRNVKPTAVEVLDEQ
KGKDKQLTLITCDDYNEETGVWETRKIFVATEVKLEHHHHHH 
 E. coli BL21 transformed with pET29 wild-type sortase or evolved sortase expression 
plasmids were cultured at 37 °C and 225 RPM in LB media supplemented with 50 μg/mL 
kanamycin. Upon OD600 = 0.8, IPTG was added to a final concentration of 0.4 mM and protein 
expression was induced for 3 h at 30 °C. The cells were harvested by centrifugation and 
resuspended in lysis buffer (50 mM Tris pH 8.0, 300 mM NaCl supplemented with 1 mM 
MgCl2, 2 units/mL DNAseI (NEB), 260 nM aprotinin, 1.2 μM leupeptin, and 1 mM PMSF). 
Cells were lysed by sonication on ice and the clarified supernatant was purified by column 
chromatography using Cobalt Talon Resin (Clontech Laboratories) following the manufacturer’s 
instructions. Fractions that were >95 % purity, as judged by SDS-PAGE, were consolidated and 
dialyzed against Tris-buffered saline (25 mM Tris pH 7.5, 150 mM NaCl) using PD-10 columns 
(GE Healthcare) and stored as 5 mg/mL stocks at 4 °C. 
Solution phase sortase transpeptidation reactions.  TMLPETG was reacted with 0.1 or 2 
molar equiv WT or 0.1 molar equiv eSrtA and 1, 10, or 100 molar equiv NH2-PEG5kDa (Nektar) 
at room temperature. At various reaction time points, a 2 µg aliquot was removed and frozen at -
80 °C. Upon completion of the study, all aliquots were thawed at room temperature and 
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incubated at 100 °C in 1x reducing buffer (Fisher Scientific), and run on a 12 % Tris PAGE gel 
(Biorad) and visualized by Coommassie staining. The stained gels were dried and scanned at 
1200 dpi on an Epson Perfection 1660 photo scanner, and quantification of the extent of TM-
PEG formation relative to unreacted TMLPETG was performed using the Gel Analyzer function in 
ImageJ software. 
 To generate TM-PEG3-N3 using sortase catalyzed transpeptidation, TMLPETG was reacted 
with 0.1 molar equiv eSrtA and 100 molar excess NH2-PEG3-N3 (Sigma) for 2 h at room 
temperature. The crude reaction mixture was run through a chromatography column containing 
Cobalt Talon Resin to remove His-tagged eSrtA, and the flow through was collected and 
dialyzed against TBS buffer (20 mM Tris pH 7.5, 100 mM NaCl) to remove excess unreacted 
NH2-PEG3-N3. Following 2 days of dialysis with regular buffer exchanges approximately every 
8 h, the final reaction mixture was concentrated and the final yield determined by total protein 
quantification per manufacturer’s protocol (Bio-Rad). 
 The extent of azide tagging of TMLPETG was determined by incubating the final reaction 
mixture with excess DBCO-biotin (Invitrogen) overnight at 37 °C. Unreacted DBCO-biotin was 
removed by 2x sequential dialysis using Zeba Spin Desalting Columns with a 7 kDa MWCO 
(Fisher Scientific). Final concentration of the dialyzed reaction mixture was determined by total 
protein quantification per manufacturer’s protocol (Bio-Rad). The extent of biotinylation of TM-
N3 by DBCO-biotin was confirmed using a fluorescent biotin quantification kit per 
manufacturer’s instructions (Fisher Scientific).   
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Abstract 
The immobilization of biologically active catalysts on solid supports is a central paradigm 
in bioprocessing industries and in the design of medical device and diagnostics. Degradation of 
surface activity in the operating environment by stresses such as oxidation, hydrolysis, and 
proteolysis often limits their long term performance. Here we show the site-specific covalent 
immobilization of biologically active molecules and their regeneration through a two-step 
stripping and recharging cycle. Reversible transpeptidation by a laboratory-evolved 
Staphylococcus aureus Sortase A (eSrtA) enabled the rapid immobilization of an 
antithrombogenic film in the presence of whole blood, as well as multiple cycles of film 
regeneration in vitro that preserved its biological activity. Moreover, medical devices can be 
modified in situ by eSrtA transpeptidation after in vivo implantation to immobilize or remove 
film constituents. These studies establish a rapid, orthogonal, and reversible surface chemistry 
scheme to regenerate selective molecular constitutents that can dramatically extend the lifetime 
of bioactive films in a manner akin to living systems. 
Introduction 
 Medical devices in blood contacting applications such as stents, extracorporeal support 
systems, and vascular access catheters are prone to life threatening complications initiated by 
maladaptive host biological responses at the blood-material interface
1,2
.  Immobilization of 
bioactive molecules and drug eluting assemblies on implantable devices has yielded promising 
combination products that abrogate thrombotic cascades and detrimental inflammation
3
, enhance 
device integration and regeneration of healthy tissue
4,5
, and inhibit microbial colonization
6
. 
Clinical translation of these strategies for permanent implants has been constrained, in part, by 
the limited therapeutic duration afforded by a finite surface reservoir of bioactive agents, as well 
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as degradation of surface components following exposure to the physiological environment
6,7
. 
Efforts to improve biostability and bioactivity have included the manipulation of surface 
properties such as hydrophilicity, charge, and topography
8
, immobilization chemistry
9,10
, as well 
as rational and evolutionary protein engineering
11
. Despite recent progress in these areas, a 
surface coating for implantable devices that reliably retains biological activity for a 
commercially and clinically viable time scale has not been developed.  
Local or systemic delivery of bioactive therapeutic payloads that target the blood 
contacting surface of medical implants may facilitate in situ regeneration of bioactivity. This 
concept has been explored previously in clinical applications such as targeted drug delivery
12,13
, 
molecular imaging
14
, and minimally invasive cell therapy
15
. In principle enzyme ligation offers 
an opportunity for catalyzing reversible bond forming reactions that could enable the molecular 
regeneration of bioactive thin films in situ. Staphylococcus aureus sortase A (SrtA) catalyzes the 
Figure 4-1 Sortase-catalyzed rechargeable assembly of LPETG-labeled thrombomodulin 
(TMLPETG) on pentaglycine modified model surfaces.  
(A) Two-step “rechargeable“ surface assembly cycle initiated by sortase-catalyzed charging of LPETG-
tagged biomolecules on pentaglycine modified surfaces, followed by sortase-catalyzed stripping to 
regenerate pentaglycine anchor sites for additional surface reaction cycles. (B) Immobilization of 1 µM 
TMLPETG on pentaglycine coated microwells using 0.1 molar equivalents evolved sortase (eSrtA), 0.1 and 
2 molar equivalents wild-type sortase (WT SrtA), or no sortase as a negative control. (C) Following 
immobilization of 1 µM TMLPETG on pentaglycine coated microwells using 0.1 molar equivalents eSrtA, 
removal of bound TM was carried out using 20 µM of either evolved eSrtA or WT SrtA with 1 mM 
triglycine. Error bars denote standard deviation (n ≥ 3). 
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covalent tra nspeptidation of a C-terminal “sorting motif” LPXTG to N-terminal oligoglycine  
(e.g. GGG) nucleophiles through an acyl-enzyme complex forming a LPXT-GGG bond
16
. Due to 
its synthetic simplicity and the very limited occurrence of the LPXTG motif in native proteins, 
SrtA-catalyzed transpeptidation has been broadly applied in protein purification, labeling, and 
immobilization onto solid supports
17-19
. However, the low catalytic activity and substrate affinity 
of wild type (WT) SrtA necessitates high molar excess of the enzyme and long incubation times 
to approach reaction completion, limiting its effectiveness and applicability. An evolved SrtA 
mutant (eSrt A) has recently been generated that exhibits 120-fold higher LPETG-ligation 
activity than the wild-type enzyme.
20
  This enzyme raises the possibility of multiple rapidly 
catalyzed c ycles of removal and reversible assembly of bioactive molecular films onto 
oligoglycine mo dified surfaces both in vitro and in vivo. 
Results   
Reversible assembly of thrombo modulin.  
We were the first to characterize the effectiveness of thrombomodulin (TM) in abrogating  
Figure 4-2 Sortase-catalyzed immobilization of LPETG-tagged thrombomodulin (TMLPETG) on 
pentaglycine surfaces in the presence of whole blood. 
Direct sortase-catalyzed assembly of TMLPETG in 50% v/v heparinized whole blood (20 U heparin/mL 
blood) at 37 °C for 1 h without additional calcium.  Evolved and wild-type (WT) sortases were tested at 2 
different TMLPETG concentrations as well as TMLPETG/sortase ratios. Error bars denote standard deviation 
(n ≥ 4). 
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tissue factor induced thrombin production under controlled venous and arterial flow conditions
21-
23
. Materials functionalized with TM, a major physiological inhibitor of thrombin generation
24,25
, 
exhibit reduced thrombogenicity in vitro and in vivo
26-35
, thereby, supporting the clinical 
feasibility of a new paradigm in an tithrombotic surface design. To demonstrate the site-specific 
reversible assembly of TM on  oligoglycine surfaces (Figure 4-1A), we first generated a 
recombinant human TM fragment containing a C-terminal LPETG motif (TMLPETG). WT SrtA 
and an eSrtA produced by directed evolution using a yeast display system were generated, as 
previously reported
20
 Model pentaglycine surfaces, which match the natural SrtA substrate on 
the S. aureus cell wall,
36
 were generated by immobilizing a biotinylated pentaglycine peptide 
(NH2-GGGGGK-biotin) on surfaces pre-coated with streptavidin.  Surface immobilization of 
TMLPETG by eSrtA yielded ~9-fold higher surface TM density than WT SrtA. Notably, this 
surface density of TM would require at least 20-fold higher quantities of WT SrtA catalyst than 
Figure 4-3 Rapid repetitive recharging of LPETG-tagged thrombomodulin (TMLPETG) on 
pentaglycine surfaces by evolved sortase A (eSrtA).  
(A) Sortase-catalyzed binding of TMLPETG on pentaglycine modified model surfaces following 1 and 16 h 
reaction were compared with the binding of biotinylated TM (TM-biotin) directly on streptavidin coated 
microwells. In parallel, TMLPETG was incubated in microwells without sortase as a negative control. (B) 
Sequential eSrtA-catalyzed charging (red) and stripping (blue) cycles of TMLETPG performed on model 
pentaglycine surfaces. (C) Cofactor activity of immobilized TM to catalyze production of activated 
protein C (aPC) following the initial assembly of TMLPETG, stripping by eSrtA, and regeneration of 
TMLPETG by eSrtA. Error bars denote standard deviation (n ≥ 3). 
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eSrtA (Figure 4-1B). Near complete removal of immobilized TM films could be achieved with  
eSrtA in 30 minutes, whereas WT SrtA was substantially less efficient w hen reacted under 
identical conditions (Figure 4-1C).  In this surface coupling scheme, the surface-binding kinetics 
of TMLPETG by eSrtA nearly matched that of biotin-avidin binding (Figure 4-2A), a well-
established bioconjugation met hod.  Up to ten repetitive recharge cycles were accomplished 
using eSrtA to reproducibly regenerate the TM film assembly (Figure 4-2B) with no significant 
loss of the ability of the TM films to catalyze generation of activated protein C (Figure 4-2C).  
These results confirm the enhanced catalytic activity of eSrtA as a critical enabling step in the 
application of a two-step strip/recharge scheme for rapid and repetitive regeneration of 
biologically active molecular films. 
 
Figure 4-4 Sequential surface reaction scheme to modify polyurethane catheters with pentaglycine 
motifs.  
(A) Reaction conditions: (1) hexamethylene diisocyanate / triethylamine; (2) DBCO-amine / 
triethylamine; (3) NH2-GGGGG-N3 
(B) Dibenzocyclooctyne (DBCO) modified polyurethane catheters reacted specifically with rhodamine 
azide probes.  Representative image of samples: (1) DBCO catheters reacted with rhodamine azide; (2) 
plain catheter reacted with rhodamine azide; (3) DBCO modified catheter reacted with rhodamine B. 
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Assembly of thrombomoduli n in whole blood.   
Due to the rarity of LPETG and GGG motifs in the physiological environment, the two-
step strip/recharge reaction by eSrtA should provide a feasible strategy to regenerate films on 
medical implants in situ. As a proof-of-concept, we demonstrated the ability to immobilize 
TMLPETG on pentaglycine surfaces in 50% v/v whole blood at 37 ºC We observed that eSrtA was 
capable of efficiently functionalizing these model surfaces >20-fold more effectively than WT 
SrtA (Figure 4-3), consistent with predictions based upon their in vitro kinetics, and at levels 
comparable to what we achieved in completely defined reaction buffer. These results highlight 
the enhanced activity of eSrtA as an enabling step towards in situ assembly of molecular films at 
the blood contacting interface of medical implants.   
 
Reversible assembly of molecular films on venous access catheters in vivo.  
Figure 4-5 Immobilization of LPETG-tagged biotin on pentaglycine modified polyurethane (PU) 
catheters by eSrtA.  
(A) Representative merged fluorescent and bright field microscopy image of PU catheters modified with 
pentaglycine motifs, and reacted with various concentrations of biotin-LPETG peptide for 30 min or 1 h. 
A total of 0.1 molar equivalent eSrtA relative to biotin-LPETG was used for all reaction conditions. At the 
end of reaction, Cy3-labeled streptavidin was incubated at 0.1mg/mL with catheters for 30 min to assess 
the surface density of biotin. (B) Fluorescence intensity was measured using Image J and expressed as 
mean ± std. dev. for 3 individual catheter segments per concentration of biotin-LPETG used. 
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Polyurethane (PU) venous access catheters are routinely used in the clinic, but have 
substantial complications related to thrombosis and infection that may be reduced by surface 
immobilization of bioactive molecular films
37-39
.  In situ eSrtA transpeptidation was used to imm 
obilize and remove LPETG-tagged probes on pentaglycine modified PU catheters deployed in 
the mouse vena cava.  PU catheters were modified with cyclooctyne motifs using a sequential 
scheme (Figure 4-4A), as previously reported
35
, and azide reactivity was confirmed using 
rhodamine azide probes (Figure 4-4B).  Azide-tagged pentaglycine peptide (NH2-GGGGG-N3) 
was used to generate pen taglycine motifs on PU catheters.  Optimal reaction parameters that  
maximized eSrtA-catalyzed assembly of a biotin-LPETG probe were first determined ex vivo 
(Figures 4-5 and 4-6).   Pentaglycine- modified catheters were deployed in the vena cava of live 
mice, followed by systemic administration of eSrtA and either LPETG tagged probes or 
Figure 4-6 Removal of LPETG-tagged biotin immobilized on pentaglycine modified 
polyurethane (PU) catheters. 
(A) Representative merged fluorescent and bright field microscopy image of PU catheters 
modified with pentaglycine motifs and reacted with biotin-LPETG/eSrtA, and stripped using 
various concentrations of GGG peptide and eSrtA as summarized in (C). Cy3-labeled streptavidin 
was incubated at 0.1mg/ml with catheters for 30 min to assess the surface density of biotin. (B) 
Fluorescence intensity was measured using Image J and expressed as mean ± standard deviation 
for three individual catheter segments per reaction condition. 
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triglycine (GGG)  to charge or strip the catheter surface, respectively.  Real time fluorescent 
imaging confirmed near complete removal of LPETG tagged near-IR probes from pentaglycine 
catheters in the presence of eSrtA and GGG within 1 h (Figures 4-7a and Figure 4-8).  Analysis 
of explanted catheters confirmed the selective immobilization or removal of biotin-LPETG 
probes from pentaglycine catheters in vivo by intravenously delivered eSrtA in 1 h (Fig. 4-7B–C 
and Figure 4-8). 
 
 
 
 
Figure 4-7 Sortase-catalyzed in situ assembly of LPETG-labeled probes on pentaglycine modified 
catheters deployed in mice vena cava. 
(A) Reversible assembly of LPETG-labeled probes on pentaglycine modified catheters deployed in vivo 
may be achieved by intravenous delivery of eSrtA and triglycine peptide. Representative real time 
fluorescent imaging of a pentaglycine modified polyurethane catheter functionalized with LPETG-labeled 
Alexa Fluor 750 deployed in mouse vena cava and stripped by intravenous delivery of eSrtA and 
triglycine. (B) In situ eSrtA-catalyzed immobilization of LPETG-tagged biotin (biotin-LPETG) probes on 
pentaglycine modified catheters deployed in mice vena cava following 1 h reaction after intravenous 
delivery of biotin-LPETG and eSrtA. (C) In situ eSrtA-catalyzed removal of LPETG-tagged biotin probes 
from pentaglycine modified catheters deployed in mice vena cava following 1 h reaction after intravenous 
delivery of triglycine (GGG) and eSrtA. Error bars denote standard deviation (n ≥ 3). 
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Discussion 
The principle that anti-thrombogenic films on blood contacting devices may yield 
improved clinical outcomes has been supported by promising results reported from randomized 
clinical trials of  heparin-bonded prostheses in the femoropopliteal position.  Enhanced 1-yr 
patency was demonstrated for heparin-bonded Dacron® grafts when compared to non-coated 
PTFE (75% vs. 58%, p = 0.037)
40
.  Likewise, superior 1-year results have been recently reported 
for heparin-bonded PTFE (Propaten®) when compared to non-coated PTFE (81% vs. 69%, p = 
0.03), particularly for those patients with critical limb ischemia (80% vs. 58%, p = 0.03)
41
.  
Initial analysis of heparin-bonded PTFE covered stents in the superficial femoral artery suggests 
a similar effect
42,43
.  Nonetheless, the surface heparin effect is not sustained; with loss of heparin 
activity on Dacron grafts within 3 months and within 6 months after implantation of Propaten 
grafts in a sheep model
44,45
. 
Figure 4-8 In situ removal of LPETG-tagged near-IR probes from pentaglycine modified 
polyurethane catheters deployed in mouse vena cava.  
(A) Catheters modified with pentaglycine peptide and conjugated with LPETG labeled Alexa Fluor 
750 was stripped by IV delivery of triglycine (400 µg) and 5’SrtA (700 µg). The near-IR fluorescent 
signal from the modified catheter was monitored using the Maestro multi-spectral fluorescence 
imaging system in real time over 70 min and (B) quantitative image analysis was performed to 
evaluate the fluorescent signal intensity of the modified catheters. 
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Current techniques to covalently modify surfaces with bioactive compounds have largely 
involved bioconjugate techniques that link nucleophilic motifs such as amines, thiols, and 
hydroxyls to their partner electrophiles
46
. Abundant presentation of these motifs in the complex 
chemical landscape of biological systems reduces the efficiency of targeting payloads for 
regenerating these device surfaces
47
.  Recent efforts to modify blood contacting surfaces with 
bioactive molecules has lead to the application of a variety of bioorthogonal coupling 
chemistries, notably Staudinger Ligation and native chemical ligation, as well as Click 
cycloaddition and intein-mediated splicing
35,48-53
.  However, these irreversible bond-forming 
approaches prohibit the in situ removal and regeneration of surface assemblies. Non-covalent 
strategies for “recharging” bioactive surfaces have been proposed through the use of metal-
affinity
54
, N-halamine structures
55
, disulfide bonds
56
, as well as biotin-avidin interaction
57
, 
nonetheless, even under controlled in vitro conditions, repetitive regeneration using these 
schemes is challenging and would not be easily adaptable to surface regeneration in vivo.  
We have determined that SrtA-catalyzed transpeptidation to site-specifically immobilize 
LPETG-tagged agents on pentaglycine modified surfaces enables the capacity to engineer highly 
specific, covalent, and rapidly “rechargeable” surfaces to sustain long term biological activity.  
In comparison with other chemoenzymatic approaches
58-60
, the enhanced kinetics and bond 
forming efficiency afforded by directed evolution of SrtA was a critical enabling technology for 
this concept.  We confirmed the capacity of eSrtA to catalyze multiple cycles of rapid assembly 
and removal of LPETG tagged biomolecules and established that such a strategy could be 
performed in the presence of whole blood.  Taken together, our findings establish the capacity to 
rapidly and reproducibly regenerate selective molecular constituents after device implantation 
with the potential to dramatically extend the lifetime of bioactive films in a manner akin to living 
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systems. It is anticipated that such a strategy could be applied to stripping and regenerating any 
of a number of potential film constituents that display finite stability or activity. 
 
Materials and Methods 
Unless otherwise specified, all reagents were purchased from Sigma-Aldrich and used 
without further purification. The peptides NH2-GGGGG-N3, NH2-GGGGGK-biotin, biotin-
LPETG, and NH2-LPETG were obtained from Genscript. LPETG-tagged Alexa Fluor 750 was 
synthesized using NH2-LPETG peptide and Alexa Fluor 750 succinimidyl ester per 
manufacturer’s instructions (Invitrogen).  
Modification of catheters in vitro.  Polyurethane catheters (SAI Infusion) with a 2 cm 
length and 1 F tip were first modified with pentaglycine anchor motifs.  Catheters were reacted 
with 16% v/v hexamethylene diisocyanate (HDI) and 4% v/v triethylamine (TEA) in toluene at 
50 °C for 1 h and rinsed in toluene for 6 h.  Isocyanate activated catheters were reacted with 1 
mg/mL dibenzocyclooctyne (DBCO)-amine linker (Click Chemistry Tools) and TEA (1% v/v) in 
toluene at 40 °C overnight, rinsed with toluene for 6 h, and dried under vacuum at 25 °C 
overnight.  DBCO activated catheters were reacted with 1 mg/mL tetramethylrhodamine -5-
carbonyl azide (Invitrogen) in 1:4 tert-butanol/PBS at 37 °C for 24 h followed by rinsing in 
methanol for 24 h to confirm surface cyclooctyne reactivity.  DBCO activated catheters were 
reacted with NH2-GGGGG-N3 at 37 °C overnight and rinsed in TBS buffer (20 mM Tris pH 7.5, 
100 mM NaCl).  Pentaglycine modified catheters were incubated with biotin-LPETG or LPETG-
labeled Alexa Fluor 750 peptide (2 µM to 100 µM) and 0.1 molar equivalents of eSrtA with 
relative to the LPETG probe concentration for 30 min or 1 h and rinsed for 4 h in TBS.  
Biotinylated catheters were incubated in 0.1 mg/mL Cy3-labeled streptavidin in TBS with 0.05% 
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Tween 20 for 30 min and rinsed overnight in TBS.  Imaging of catheters was carried out using 
the Zeiss Discovery V20 Stereo Microscope and quantitative image analysis by ImageJ was 
performed to determine fluorescence intensity. 
In situ modification of catheters deployed in mice. Pentaglycine modified catheters 
were deployed approximately 1 cm within the vena cava via the femoral vein of C57BL/6 mice. 
All animals were maintained under anesthesia with isoflurane or ketamine on a heating pad.  In 
order to functionalize pentaglycine modified catheters in situ, a 200 µL dose of 4 nmol eSrtA, 40 
nmol LPETG-tagged biotin, and 20 U of heparin were injected intravenously through the 
catheter inlet.  To demonstrate in situ removal of LPETG probes from pentaglycine modified 
catheters, a 200 µL dose of 40 nmol eSrtA, 2 µmol triglycine peptide, and 20 U of heparin were 
injected intravenously through the catheter inlet.  After 1 h reaction, the mice were sacrificed and 
catheters were explanted and incubated in streptavidin-Cy3 (30 min) and washed with TBS 
buffer (2 h).  Fluorescent and bright field microscopy images were obtained to detect biotin 
groups on the catheter surface.  Real time tracking of the in situ removal of LPETG-tagged 
Alexa Fluor 750 was carried using a Maestro Multi-Spectral in vivo fluorescence imaging system 
with near-IR filter sets. Images were taken using a monochromatic 12-bit camera, and analyzed 
using ImageJ to determine fluorescence intensity. 
Statistical Analysis. Two-tailed student’s t-test assuming unequal variances was used to 
test for statistical significance between the means of two groups. 
All other methods are as described in Chapter 3 
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Abstract 
S. aureus sortase A catalyzes the transpeptidation of an LPXTG peptide acceptor and a 
glycine-linked peptide donor and has proven to be a powerful tool for site-specific protein 
modification. The substrate specificity of sortase A is fairly stringent, limiting its broader utility.  
Here we report the directed evolution of sortase A to recognize two altered substrates, LAXTG 
and LPXSG, with high activity and specificity.  Following nine rounds of yeast display screening 
integrated with negative selection based on competitive inhibition with off-target substrates, the 
evolved sortases exhibit specificity changes of up to 51,000-fold relative to the starting sortase 
without substantial loss of catalytic activity.  The specificities of these reprogrammed sortases 
are sufficiently orthogonal to enable the simultaneous conjugation of multiple peptide substrates 
to their respective targets in a single solution.  We demonstrated the utility of these evolved 
sortases by using them to effect the site-specific labeling of unmodified, endogenous fetuin A in 
human plasma, the conjugation of orthogonal fluorescent peptides onto surfaces, and the 
synthesis of tandem fluorophore-protein-PEG conjugates in two therapeutically relevant 
fibroblast growth factor proteins, FGF1 and FGF2.  
Introduction 
  The modification of proteins enables applications including the manipulation of 
protein pharmacokinetics,
1,2
 the study of protein biochemistry
3
, the immobilization of proteins on 
solid support
4
, and the synthesis of protein-protein fusions that cannot be expressed in cells
5,6
.  
An attractive approach for the synthesis of such conjugates attaches molecules site-specifically to 
proteins using epitope-specific enzymes.  Such a strategy can bypass the challenges of 
bioorthogonality and chemoselectivity through the careful choice of enzyme and tag.  
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Techniques to implement this approach, however, are commonly limited by the requirement of 
cumbersome and poorly-tolerated fusion tags, or by rigidly defined donor substrate specificity.   
 The bacterial transpeptidase S. Aureus sortase A (SrtA) mediates the anchoring of 
proteins to the bacterial cell wall and has been widely exploited in bioconjugate synthesis
7
.  SrtA 
recognizes a small, 5-amino acid “sorting motif” (-LPXTG, where X = any amino acid) that can 
be incorporated into many proteins of interest.  Upon binding a sorting motif, SrtA cleaves the 
scissile Thr-Gly peptide bond via a cyste ine protease-like mechanism, resulting in loss of the C-
Figure 5-1 Schematic of yeast display-based negative selection 
A. Schematic representation of the Sortase A reaction.  SrtA recognizes the LPXTG peptide sequence, 
then cleaves between the T-G bond to form a covalent intermediate, SrtA(LPXT) while ejecting the C-
terminal region.  This stable thioester then catalyzes the equilibration with externally provided C-
terminal regions.  B. Bond-forming yeast display selection scheme incorporating negative selection.  
Clockwise from top left: Specific (red) and promiscuous (blue) enzymes are displayed as C-terminal 
Aga2p fusions in our bond forming yeast display system.  Next, S6 peptide-containing Aga1p molecules 
are loaded with a selection acceptor substrate, such as GGG-CoA, displaying it at high effective molarity 
to the displayed enzyme.  Modified cells are incubated with a small amount of a biotinylated target 
moiety (red) and a large amount of an unbiotinylated off-target moiety (blue).  Enzyme is then cleaved 
away by TEV protease and cells are labeled for biotinylation as well as protein display, sorted for 
activity and display levels, and optionally rediversified for further selection. 
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terminal glycine to yield a thioacyl intermediate.  This intermediate then reacts with an N-
terminal Gly-Gly-Gly motif to result in a -LPXTGGG- conjugate (Figure 5-1a).  The small size 
of the SrtA sorting motif and the synthetic accessibility of Gly-Gly-Gly-linked substrates have 
led to the use of SrtA in a wide variety of applications, including the synthesis of protein-
protein
6
, protein-nucleic acid
8
, protein-lipid
9
, and protein-surface
10
 conjugates. 
 The utility of wild-type SrtA has been limited by two key factors.  First, its poor catalytic 
activity limits its use primarily to applications in which it can be used in superstoichiometric 
amounts, and over long timescales, such as small-scale bioconjugate synthesis.  The modest 
catalytic activity of wild-type SrtA also reduces reaction yield and can lead to the formation of 
substantial quantities of stable thioacyl intermediates.  To overcome this limitation, we 
previously reported the development of a selection for the evolution of bond-forming enzymes 
(Figure 5-1b), and the application of this selection to evolve a highly active SrtA variant, eSrtA, 
with five mutations relative to wild-type SrtA and approximately 140-fold higher catalytic 
activity than the wild-type enzyme.
11
 
 A second limitation of both SrtA
12
 and eSrtA is their fairly stringent requirement for 
substrates containing LPXTG.  This constraint precludes the use of these enzymes to modify 
proteins lacking this particular sequence (naturally or through genetic modification), and also 
prevents their use in more complex syntheses in which multiple sortase enzymes conjugate 
orthogonal substrates onto a single protein scaffold or onto multiple protein targets.  Previous 
approaches to addressing this limitation have included the directed evolution of a catalytically 
weakened but promiscuous SrtA variant recognizing XPXTG motifs
13
, as well as the use of 
homologous sortase enzymes possessing different specificity
14
.  These approaches, however, 
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have thus far produced enzymes with substantially lower activity relative to wild-type SrtA or 
eSrtA and cannot be used to modify arbitrary targets of interest 
13,15
. 
 In this work we developed and applied a modified version of a bond-forming enzyme 
screening system to evolve SrtA variants with dramatically altered, rather than broadened, 
substrate specificity.  Over the course of nine rounds of mutagenesis and fluorescence-activated 
cell sorting (FACS), we isolated eSrtA variants that recognize either LPXSG or LAXTG with a 
minimal loss of activity and up to a 51,000-fold change in specificity relative to eSrtA.  We 
applied these reprogrammed sortases to the synthesis of doubly modified fluorophore-protein-
PEG conjugates to demonstrate the rapid construction of complex protein conjugates through 
multi-step transpeptidation.  In addition, we used these evolved sortases to achieve the post-
translational modification of endogenous fetuin A, a protein that cannot be efficiently modified 
by eSrtA because it lacks an LPXTG motif, in unmodified human plasma.  Finally, we used the 
evolved sortases to immobilize fluorophore-linked peptides onto GGG-modified well plates to 
demonstrate orthogonal surface functionalization.  Collectively, these findings represent a facile 
approach for generating sortase enzymes with tailor-made substrate specificities and expand 
substantially the number of highly active, orthogonal sortase enzymes available for protein 
conjugation applications. 
Results 
A competitive inhibition strategy for sortase evolution 
 To evolve eSrtA variants with altered substrate specificity, we combined our previously 
described modified yeast display screen
11
 with competitive inhibition to enable negative 
selection pressure against promiscuous enzymes (Figure 5-1b).  We hypothesized that presenting 
an enzyme with a limiting quantity of biotinylated target substrate in the presence of a large 
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excess of non-biotiny lated off-target substrate, followed by screening for biotinylated cells, 
would create evolutionary pressure favoring enzymes with both high activity and high 
specificity.  Enzymes that survive sc reening will preferentially process the target substrate, 
resulting in cell biotinylation, rather than expend their single turnovers on processing off-target 
substrates that do not result in cell biotinylation (Figure 5-1b).  We envisioned that positive and 
negative selection pressures could be modulated by varying the concentrations of biotinylated 
target substrate and non-biotinylated off-target substrates. 
 To test the ability of cognate LPETG substrate (Km = 0.2 mM) to compete with a 
Figure 5-2 Validation of SrtA competitive negative selection.  
ICY200 Yeast displaying eSrtA were induced overnight with SGR media, then incubated for one hour 
with 10μM Btn-LAETGG peptide and between 100nM and 1mM non-biotinylated LPETGG peptide in 
TBS supplemented with 5mM CaCl2.  Cells were then cleaved using TEV, labeled for expression and 
activity as described and assayed flow cytometrically.  Signal reduced to that of unlabeled control at 
levels above 10μM LPETG. 
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candidate LAETG target (Km = 6.1 mM), we used a strain of S. cerevisiae displaying eSrtA in 
the context of our bond-forming scre en.  Loading the Aga1 domain with GGG-CoA, we 
incubated cells with 10 μM bioti n-LAETG and a range of 100 nM to 1 mM non-biotinylated 
LPETG for 1 hour (Figure 5-2).  We observed 50% inhibition of cell biotinylation with 10 μM 
LPETG, and virtually complete inhibition b y 100 μM LPETG.  These results suggest that in the 
context of our screen, th e KI of a free competitive substrate i s substantially more potent than its 
Km when treated as a substrate, possibly because the single-turnover nature of the yeast display 
system strongly penalizes candidate enzymes that accept non-biotinylated substrates.  Taking this 
observation into account, we perform ed all subsequent screens for altered SrtA specificity in the 
presence of 1 μM to 1 mM LPETG.  
 
Table 5-1 Complete evolution program for eSrtA(2A) and eSrtA(4S) substrates.   
In each case, libraries were iteratively selected against increasing concentrations of the undesired substrate 
LPETGG in the presence of decreasing concentrations of biotinyl-LAETGG or LPESGG.   
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Initial evolution of eSrtA variants with altered substrate preference  
 Because binding-pocket geometries of SrtA in the previously reported apo-LPETG 
crystal structure
16
, apo-LPETG NMR structure
17
, and holo-LPETG NMR structure
18
 are diverse,  
we used broad, unbiased mutagenesis to gen erate initial eSrtA diversity.  We randomized at a 
2% level the entire  SrtA gene (441 bp) via chemical mutagenesis (8 mutations per gene on 
average), transformed the resulting gene pool into y east to generate libraries of 10
7
 to 10
8
 eSrtA 
variants, and then screened the resulting libraries with either biotin-LAETG or biotin-LPESG in 
Figure 5-3 Activity levels (kcat/Km, in M
-1
s
-1
) of the most abundant clones from each of the measured 
rounds of selection. 
In each case, the most abundant single clone from each round was expressed and purified from E. coli, 
then characterized using an in vitro HPLC assay against either Abz-LPETGK(Dnp)CONH2, Abz-
LAETGK(Dnp)CONH2 or Abz-LPESGK(Dnp)CONH2 in order to determine kcat, Km and kcat/Km for each 
enzyme against either the wild type substrate LPETG or the new target substrates (Table 5-3).  
(kcat/Km)target:(kcat/Km)LPETG was observed to change significantly across nine rounds of screening and 
mutagenesis, changing by a factor of 51,000 for LAETG, from 1:103 (eSrtA) to 510:1 (eSrtA(2A-9)) and 
by a factor of 125 for LPESG, from 1:5 (eSrtA) to 25:1 (eSrtA(4S-9)). 
 
 
120 
 
the presence of inhibitory concentrations of LPETG (Table 5-1).  Starting eSrtA exhibits a 103-
fold preference for  LPETG over LAETG, and a 5-fold preference for LPETG over LPESG 
(Figure 5-3). 
 Three rounds of whole-gene mutagenesis and screening yielded two converged clones, 
eSrtA(2A-3) and eSrtA(4S-3), each of which containe d between eight and ten coding mutations 
Figure 5-4 Mutational context of eSrtA variants of altered specificity.   
A. The holo-enzyme structure is shown with a model LPET-thioester bound, with the mutated residues 
I182 and V168 highlighted in addition to their surrounding amino acid context.  Notably, further 
mutation of A92 or L169 failed to improve the specificity or activity of the evolved mutants. B,C. 
Mutations present in C, eSrtA(2A-9) and D, eSrtA(4S-9) highlighted in red on the wild type holo-SrtA 
NMR structure. 
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relative to eSrtA.  Using an established HPLC assay
19
, we determined that mutants 2A-3 and 4S-
3 exhibited substantially altered substrate preferences of 1.4-fold preference for LPETG over 
LAETG (reduced from 103-fold) and a  245-f old preference for LPESG over LPETG (reversed 
from a 5-fold preference for LPETG), but at the expense of > 10-fold reduced catalytic efficiency 
(Figure 5-3).  By  analyzing the mutations that emerged after round 3 in the context of the SrtA 
holo-LPETG NMR structure, we identified a cluster of three mutations in each mutant that are 
predicted to make contacts with the LPETG substrate in eSrtA.  In the case of eSrtA(2A-3), these 
mutations are K162R, V168I and I182F, while in the case of eSrtA(4S-3), these changes are 
A104T, A118T and I182V (Figure 5-4).  We hypothesized that these mutations were principally 
responsible for altering the substrate binding site geometry to accommodate the new targets, with 
V168I and I182F collectively providing additional steric bulk to complement the smaller alanine 
side chain at substrate position 2, and A104T and A1 18T altering the active site geometry to 
discriminate the extra methyl group in threonine from serine at substrate position 4. 
 To test this hypothesis, we generated candidate “minimal mutant” eSrtA(2A-3.5) and 
eSrtA(4S-3.5) enzymes containing only those three mutations corresponding to predicted first-
shell contacts in each evolved sortase.  Both minimal mutants exhi bited substrate promiscuity, 
processing both the wild-type LPETG and their new respective LAETG or LPESG targets with 
comparable efficiency (Figure 5-3), albeit with ~100-fold lower activity than that of eSrtA 
processing its own native LPETG substrate.  While these variants showed dramatically reduced 
performance in nearly all respects, their broad substrate scope led us to suspect that they would 
serve  as strong starting points for the further evolution of altered sortase specificity.  Moreover, 
these results validated the importance of the A104/A118/I182 cluster for recognition of the T4 
residue and of the V162/V168/I182 cluster for recognition of the P2 residue.  Taken together, 
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these results suggest that mutations in the binding groove of eSrtA contribute to changes in 
specificity, but are not sufficient to impart high substrate specificity and activity. 
Secondary evolution of eSrtA variants with altered substrate specificity 
 Next we generated site-saturation libraries based on the eSrtA(2A-3.5) and eSrtA(4S-3.5) 
minimal mutants.  Using degenerate NNK codons, we randomized residues 104, 168, and 182 in 
eSrtA(2A-3.5), and residues 104, 118, and 182 in eSrtA(4S-3.5).  Additionally, we used PCR 
mutagenesis to further diversify the se libraries in an untargeted manner at a frequency of ~1% 
per residue.  Screening of these librar ies against their target substrate s in the presence of ten-
fold higher concentrations of non-biotinylated LPETG yielded the round 4 variants eSrtA(2A-4) 
and eSrtA(4S-4 ), each of which acquired novel mutations.  In eSrtA(2A-4), A104H, V168I, and 
I182V resulted in a dramatic specificity change relative to eSrtA(2A-3.5), for the first time 
generating an enzyme that reacted preferentially with LAETG over LPETG (73-fold preference) 
(Figure 5-3).  In the case of eSrtA(4S-4), A104V, A118T, F122S, and I182V imparted slightly 
improved preference t owards LPESG relative to the promiscuous mutant eSrtA(4S-3.5), 
resulting in a 2-fold preference for LPESG over LPETG.  
 To more fully explore the sequence space of residues mutated in round 4 clones, we 
subjected these loci to site saturation mutagenesis.  In round 5, we applied NNK mutagenesis to 
the most frequently mutated residues among clones emerging from round 4 (positions 162, 168, 
and 182 in eSrtA(2A-4), and positions 118, 122, and 182 in eSrtA(4S-4)), and also mutated the 
rest of the eSrtA gene at a ~1% frequency.  Screening of the resulting libraries yielded variants 
eSrtA(2A-5) and eSrtA(4S-5), each of which included a mixture of mutations at targeted and 
untargeted residues.  In the case of eSrtA(2A-5), we observed library-wide convergence towards 
R99H and K138I mutations in addition to I168V reversion mutations.  In the case of eSrtA(4S-
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5), we identified N98D, F122A and A118S mutations, with A118T mutations forming a minor 
subpopulation, not present in the consensus eSrtA(4S-5) sequence.  Expression, purification, and 
assaying of these round 5 clones revealed that eSrtA(2A-5) possessed 2-fold improved substrate 
specificity and 6-fold improved catalytic efficiency when compared with eSrtA(2A-4), while 
eSrtA(4S-5) possessed 4-fold improved substrate specificity and 10-fold improved catalytic 
efficiency when compared with eSrtA(4S-4)  (Figure 5-3). 
 Following these gains, we repeated this approach of saturation mutagenesis on both 
newly discovered mutations, as well as revisiting the original pentamutant mutations from the 
eSrtA starting material.  Starting from eSrtA(2A-5), we combines five libraries in which 
positions 99 and 138 were randomized, in addition to either residue 160, 165, 189, 190, or 196.  
Similarly, starting from eSrtA(4S-5), we randomized position 132, in addition to one of residues 
in positions 160, 165, 189, 190, or 196, before combining the resulting five libraries.  Untargeted 
mutagenesis and screening as before provided variants eSrtA(2A-6) and eSrtA(4S-6).  We 
observed the reversion H99R as well as D160K, K152I, and K138P in eSrtA(2A-6).  In the case 
of eSrtA(4S-6), A118T was a predominant mutation, in addition to K134R and E189F.  These 
variants exhibited only marginal improvements in catalytic activity and specificity relative to 
round 5 clones (Figure 5-3), suggesting that further targeted mutagenesis would not yield further 
gains in performance. 
 Given that substrate specificity and catalytic activity were comparable among clones 
emerging from rounds 5 and 6, we hypothesized that the selective advantage of eSrtA(2A-6) and 
eSrtA(4S-6) over their ancestors must have arisen from reduced substrate hydrolysis.  To 
decouple hydrolysis from overall enzymatic efficiency, we measured the concentration of GGG 
at which the rates of acyl-enzyme hydrolysis and transpeptidation are equal, which we define as 
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the parameter KH.  We found that eSrtA(2A-6)  (KH = 149 ± 63 µM) possessed significantly 
improved hydrolytic performance when compared with eSrtA(2A-5) (KH = 731 ± 235) and that 
eSrtA(4S-6) (KH = 116 ± 10 µM) was significantly improved relative to eSrtA(4S-5) (KH = 190 
± 16 µM). 
 Taken together, these results suggest that the use of whole-gene mutagenesis to identify 
target loci for site saturation mutagenesis provides access to eSrtA variants with substantially 
altered substrate specificities.  Despite the strong gains observed in rounds 4 and 5, however, we 
observed no significant activity gains in round 6, suggesting that these evolved enzymes were in 
a local fitness maximum. 
Evolving improved activity in eSrtA mutants with altered specificities 
 Next we partially randomized all of the sites that were mutated among clones in rounds 
4-6.  For each target site, we created degenerate codon libraries designed to achieve a 27% 
mutagenesis rate at each nucleotide of each codon observed to change from our eSrtA starting 
scaffold.  We applied this scheme to residues 94, 98, 99, 104, 160, 162, 165, 182, 189, 190, and 
196 in both eSrtA(2A-6) and eSrtA(4S-6) and further applied broad spectrum mutagenesis to 
each library at a level of approximately 1%.   
We screened each library at slowly increasing stringency.  Round 7 was sorted three 
times at stringency levels comparable to that of round 6 (Table 5-1) in order to enable neutral 
drift, and when tested for activity en masse revealed significant cell biotinylation after only five 
minutes of incubation with substrate.  The round 7 survivors were then randomly mutagenized to 
yield the round 8 library.  Round 8 was sorted four times at a reduced five-minute incubation 
time, maintaining the library at the maximum activity level attained during round 7.  At this 
point, significantly improved activity was observable in the final round 8 population.  Harvesting 
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and randomly mutating the round 8 library led to the round 9 library, which was then subjected 
to five rounds of sorting with 5-minute incubation times as well as gradually decreasing 
concentrations of biotinylated substrate (down to a minimum of 6 nM in the case of LPESG 
selections and 8 nM in the case of LAETG selections) and increasing concentrations of up to 4 
mM of non-biotinylated LPETG.  These libraries converged on variants eSrtA(2A-9) and 
eSrtA(4S-9), each of which possessed four to five mutations relative to their round 6 
counterparts.  Expression, purification and testing of these mutants revealed them to be highly 
active on their target substrates, with minimal off-target activity against their starting LPETG 
substrates.  The overall changes in substrate specificity of eSrtA(2A-9) and eSrtA(4S-9) relative 
to eSrtA are 51,000- and 120-fold, respectively (Figure 5-3).   
 Clone eSrtA(4S-9) showed greatly improved specificity for LPESG over LPETG (25-
fold) when compared with eSrtA‟s opposite starting preference for LPETG over LPESG (5-fold) 
with negligible activity on LAETG substrates.  We hypothesized that this much higher 
specificity for LPESG was in part caused by the LPXS-eSrtA(4S-9) intermediate coupling more 
efficeintly to GGG compared to the LPXT-eSrtA(4S-9) intermediate.  In order to test this 
hypothesis, we measured KH of eSrtA(4S-9) for LPETG and for LPESG, and observed that 
KH,LPETG (295 ± 18 μM) was nearly twice that of KH,LPESG (174 ± 32 μM).  These results show 
that eSrtA(4S-9) achieves its specificity via a combination of selectively binding LPESG over 
LPETG, as well as reduced stability of the mis-charged LPET-SrtA intermediate. 
 Similarly, eSrtA(2A-9) showed much higher specificity than eSrtA for its target 
substrate, with a nearly 500-fold preference for LAETG over LPETG as compared to eSrtA‟s 
103-fold opposite starting specificity for LPETG over LAETG, and negligible activity on 
LPESG.  Unfortunately, the poor affinity of eSrtA(2A-9) for LPETG precluded the measurement 
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of KH,LPETG for this variant.  However, measuring KH,LAETG (18.7 ± 3.3 µM) revealed it to have 
substantially improved hydrolytic performance compared to that of eSrtA, and comparable to 
that of wild-type SrtA. 
 In order to test if eSrtA(2A-9) and eSrtA(4S-9) retain similar global specificity profiles to 
that of wild-type SrtA, we assayed the activity of both enzymes on peptides related to their 
reprogrammed targets, as well as on the LPETG starting peptide (Table 5-2).  Among substrates 
containing A, G, P, S or V at position 2, eSrtA(2A-9) exhibited greatest activity on LAETG, with 
LSETG showing more than 10-fold lower activity, and LGETG and LPETG both showing more 
than 100-fold diminished conversion, and LVETG showing no detectable activity (Table 5-2).  
Table 5-2 Table of eSrtA(2A) and eSrtA(4S) small amino acid specificity.   
As described above, 6.4, 64 or 640 nM eSrtA(2A), or 5.5, 55 or 550 nM eSrtA(4S) were incubated with 
10µM of the listed peptide substrates in SrtA reaction buffer for 15 minutes, then quenched and analyzed 
by HPLC.  eSrtA(2A-9) showed significant (greater than on LPETG) reactivity only with LAETG, 
LSETG and LGETG, while eSrtA(4S-9) showed significant reactivity only with LPESG and LPEAG. 
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For eSrtA(4S-9), similar substrate  profiling on A, G, S, T and V substitutions at position 4 
revealed that eSrtA(4S-9) has ve ry low activity on LPEGG, LPETG, and LPEVG substrates, but  
considerable activity against LPEAG substrates (Table 5-2).  Indeed, eSrt(4S- 9) possesses 62% 
of LPESG-type activity on LPEAG substrates (Table 5-3). 
 Collectively, these results establish that eSrtA(2A-9) and eSrtA(4S-9) evolved altered but 
fairly stringent specificity  compared with eSrtA, at least in part modulated through the 
Table 5-3 Selected kinetic parameters for Wild Type, eSrtA, eSrtA(2A.9) and eSrtA(4S.9) for each 
of their selected substrates.   
In each case, rate constants were determined by measuring enzyme velocity at 8 different substrate 
concentrations by HPLC assay, then fit using nonlinear regression to the Michaelis-Menten equation, 
yielding kcat and Km.  KH was measured by determining the enzyme hydrolysis rate in the absence of GGG 
kH, in addition to the kcat and Km,GGG for GGG with acceptor substrate concentration fixed. KH was then 
calculated by the direct assay using the modified Michaelis-Menten equation v =  Enz kcat
 GGG + KH
 GGG +Km,GGG
. 
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hydrolytic stability of their acyl-enzyme intermediates.  Both evolved round 9 clones strongly 
prefer their new LAXTG  or LPXSG targets over the canonical LPXTG substrate, yet maintain 
overall catalytic efficiency within 2-fold of that of eSrtA (Table 5-3). 
eSrtA(4S-9) modifies endogenous fetuin A in human plasma 
In light of the known activity of eSrtA in human serum
20
 and the highly altered 
specificity of eSrtA(4S-9), we hypothesized that eSrtA(4S-9) could catalyze the site-selective 
modification of endogenous LPXSG or LPXAG motifs in the human proteome.  Based on an 
initial survey of the Uniprot protein database
21
, we identified 199 candidate proteins with 
LPXSG or LPXAG motifs known to exist in the human proteome.  Cross-validation against the 
Plasma Proteome Database
22
 identified only 36 proteins known to be present at detectable 
concentrations in human plasma.  Due to th e frequent occlusion of such tags in their folded 
Figure 5-5 Use of evolved eSrtA variants to label endogenous substrates.   
(A) Treatment of human plasma with 1μM selected SrtA variants for 2 hours at room temperature in the 
presence of 1mM GGGK(Biotin) and with or without 10mM CaCl2 supplement.  A clear labeling product 
is produced with a molecular weight of approximately 50 kDa.  Scale-up and biotin pulldown followed by 
proteomic analysis identified this protein as fetuin A, which subsequent antibody labeling (B) confirmed.  
The ~1kDa mass shift corresponding with GGG-Btn installation is clearly visible in the eSrtA(4S-9), 
10mM supplemental CaCl2 sample.  Densitometry of these bands suggest overall labeling efficiency of 
0.6% by eSrtA in the presence supplemental calcium, 1.8% by eSrtA(4S-9) in the absence of 
supplemental calcium, and 57.6% by eSrtA(4S-9) in the presence of supplemental calcium. 
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state, we hypothesized that only a small fraction of the se 36 candidate proteins would be 
accessible to transpeptidation by a functional enzyme.   
We tested the ability of eSrtA(4S-9) to label proteins in human plasma by co-incubating 
whole plasma with 1 µM eSrtA(4S-9) in the presence of 1 mM Gly-Gly-Gly-Lys(Biotin) for 2 
hours at room temperature in the presence or absence of 10 mM CaCl2.  Immunoblot and biotin 
capture each identified a single transp eptidation product (Figure 5-5), identified by mass 
spectrometry and confirmed by Western blot as fetuin A.  As a systematic regulator of tissue 
mineralization,
23
 the selective in vivo and in vitro modification of fetuin A may be useful in the 
study of pathogenic biomineralization, as well as the diagnosis or potential therapeutic 
intervention of fetuin-associated hemodialysis outcomes
24
, malnutrition-inflammation-
atherosclerosis syndrome
25
 and P. berghei pathogenesis
26
.  Fetuin A contains an LPPAG 
sequence that our studies above suggest should be a substrate for eSrtA(4S-9), but that should 
not be a substrate for eSrtA.  Ind eed, eSrtA showed no processing of fetuin A in the absence of 
supplemental calcium, and only modest fetuin A conjugation efficiencies (90-fold lower than 
that of eSrtA(4S-9)) in the presence of 10 mM supplemental CaCl2. 
These findings demonstrate the ability of evolved reprogrammed sortase enzymes to 
conjugate substrates to endogenous human proteins without chemical or genetic intervention.  
The high activity level of eSrtA(4S-9) in the absence of supplemental calcium demonstrates that 
evolved eSrtA variants can modify  endogenous proteins with no additional cofactors. 
Reprogrammed sortases enable the facile synthesis of complex bioconjugates 
The multiple modification of a protein‟s N- and C- terminus using only a single SrtA 
variant is severely hindered by competing reactions of protein oligomerization and 
circularization whenever a reactive C-terminal sorting signal and N-terminal GGG are both 
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present (Figure 5-6). Orthogonal SrtA variants have previously been used in the N- and C-
terminal functionalization of target proteins
14,27
.  However, in these applications the low activity 
and poor orthogonality of the enzymes greatly limited the scope of available reactions
27
.  In order 
to test whether the high activity and altered specificity of eSrtA(2A-9) and eSrtA(4S-9) can 
overcome these limitations, we attempted to synthesize dual N- and C-terminally functionalized 
Figure 5-6 Circularization of GGG-FGF-LPESG by eSrtA in Dual Labeling.  
Reactions between SUMO-TEV site-FGF1-LPESG-His6, 0.5eq TEV Protease, and either 0.2eq eSrtA or 
eSrtA(2A) in the presence of 10 or 100µM Btn-LAETG for 4 hours.  In situ digestion of the TEV 
cleavage site exposes an N-terminal GGG, which is ideally then reacted with LAETG.  However, in the 
presence of the off target site LPESG, a promiscuous sortase irreversibly reacts with it to cleave away the 
C-terminal his tag, and circularize the resulting protein.  This competing side-reaction introduces a side 
product that copurifies with nearly all FGF conjugates, significantly reducing both purity and yield in the 
absence of orthogonal enzymes. 
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proteins of biomedical importance.  Fibroblast Growth Factor 1 (FGF1) is currently being 
evaluated for the treatment of ischemic disease and is limited in its efficacy by low in vivo  
stability
28
.  Fibroblast Growth Factor 2 (FGF2) is an angiogenic factor that has been investigated 
previously as a wound healing factor
29
, but its translation into the clinic has been also limited by 
poor biostability
30
. 
We expressed recombinant FGF1 and FGF2 as SUMO-TEV-GGG-FGF-LPESG-His6 
constructs.  Due to the close proximity of the FGF N- and C-termini, transpeptidation attempts 
using an unprotected N-terminus, or using non-orthogonal enzymes, generated only circularized 
Table 5-4 Yields of FGF/GGG-PEG Semisynthesis.   
750-FGF-GGG-PEG conjugates were synthesized as described in main text, using intermediate 
purification by Ni-NTA filtration to remove SrtA catalyst and unreacted starting material, then 
concentrated against 10kDa membranes to eliminate residual GGG-PEG and leaving groups.  These 
conjugates were assayed for purity via denaturing gel, and for overall yield by BCA assay, shown above.  
Notably, FGF2 conjugates showed uniformly poorer yield than FGF1 conjugates, owing both to their 
lower starting purity than FGF1 (<50%, as opposed to >90%) and to their smaller reaction scale (0.5mg 
vs 8mg). 
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FGF as product (Figure 5-6).  We used evolved eSrtA(4S-9) to conjugate 10 kDa PEG-GGG, 10 
kDa bis-PEG-GGG, 10 kDa 4-arm PEG-GGG, or 10 kDa Biotin-PEG-GGG to this protein.  The 
loss of the C-terminal His6 tag, along with the use of His6-tagged reagents, allowed the facile 
Figure 5-7 N- and C-terminal labeling of the Fibroblast Growth Factors FGF1 and FGF2.   
Tandem SUMO-TEV Cleavage Site-FGF1/2-LPESG-His6 constructs were expressed in BL21 (DE3) cells 
and purified by Ni(NTA) chromatography.  These constructs were then treated with 0.2 eq eSrtA(4S-9) in 
the presence of 1mM GGG-PEG and purified by filtration through a plug of Ni-NTA resin followed by 
concentration against a 10kDa MWCO membrane.  These were then treated with 0.2 eq eSrtA(2A-9) in the 
presence of 10eq AlexaFluor750-LAETGG and purified once more by ion exchange chromatography to 
give the expected conjugates in listed yield. To assess labeling specificity, conjugates were run on an SDS-
PAGE gel and scanned for fluorescence at 700 nm 
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purification of these conjugates from the initial reaction mixture.  In situ cleavage of the linker 
by TEV protease generated an N-terminal GGG, which was then reacted with an Alexa Fluor® 
750-linked LAETG peptide using evolved eSrtA(2A-9) to afford the final 750-LAETG-FGF-
LPESG-PEG bioconjugates in moderate yield (15-30% yield at 8mg scale, see Table 5-4) and 
high purity (Figure 5-7).   
These results establish that eSrtA(2A-9) and eSrtA(4S-9) collectively form an orthogonal 
protein conjugation enzyme pair, enabling the facile synthesis of complex bioconjugates at 
substantially improved scale and yield relative to previous methods
14
.  The facile and parallel 
synthesis of milligram quantities of dual PEG- and fluorophore-conjugated proteins of clinical 
interest may facilitate the high-throughput synthesis and screening of bioconjugates at scales 
relevant to preclinical studies.  
eSrtA(2A-9) and eSrtA(4S-9) modify material surfaces orthogonally and with high activity 
Finally, encouraged by the effectiveness of eSrtA(2A-9) and eSrtA(4S-9) for protein 
semisynthesis, we tested their potential utility for functionalizing surface materials.  Previous 
methods of biofunctionalization have been successful in generating materials with improved 
biocompatibility
31-33
, however these methods are only compatible with end-point immobilization 
of a single protein.  Techniques for the orthogonal or multi-component immobilization of several 
proteins to a single material target could enable the synthesis of more sophisticated protein-
linked materials. 
To test the ability of our evolved eSrtA variants to selectively modify their cognate 
substrates in complex mixtures, we measured their ability to modify GGG-functionalized 
amphiphilic diblock polypeptide surfaces, rather than soluble substrates, using fluorophore-
conjugated LAETG or LPESG (Figure 5-8).  We generated GGG-PEG-functionalized 96-well 
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plates, to which we added either Alexa Fluor® 488-LAETG or Alexa Fluor® 647-LPESG in the 
Figure 5-8 Functionalization of GGG-Diblock by eSrtA(2A) and eSrtA(4S).   
Reactions between eSrtA(2A), eSrtA(4S) and amphiphilic diblock polypeptide (ADP).  ADP was co-
incubated with Alexa Fluor® 488-LAETG, Alexa Fluor® 647-LPESG, eSrtA(2A) and/or eSrtA(4S).  
These reactions were then run out on denaturing gel and visualized using either coomassie stain, 488 
fluorescence or 647 fluorescence.  As shown, significant peptide-diblock reaction was observed only for 
cognate pairs of enzyme and sorting signal, with no detectable off-target interactions. 
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presence of eSrtA(2A-9), eSrtA(4S-9), or both.  Each enzyme exhibited significant activity only 
on its cognate substrate, and each was capable of modifying surfaces to a high degree of 
functionalization when combined with its cognate substrate (Figure 5-9).  These results 
collectively suggest that eSrtA(2A-9) and eSrtA(4S-9) are capable of mediating the simultaneous 
conjugation of multiple distinct compounds onto GGG-functionalized surfaces with very little 
cross-reactivity.   
Figure 5-9 Functionalization of solid substrate using eSrtA(2A-9) and eSrtA(4S-9).   
GGG-PEG(5kDa) coated 96 well plates were reacted with pools containing enzyme and fluorophore-
peptide conjugates, then their total fluorescence was measured at 488 nm or 647 nm, and collectively 
normalized to the fluorescent intensities obtained from the groups „eSrtA(2A-9) + 488-LAETG‟ or 
„eSrt(4S-9) + 647-LPESG‟. In each case, overall labeling was maintained at a high level using only small 
amount of enzyme, with minimal cross-reactivity owing to the high overall specificity of eSrtA(2A-9) and 
eSrtA(4S-9). 
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Discussion 
We applied a modified yeast display selection strategy to evolve highly active eSrtA into 
reprogrammed, orthogonal variants eSrtA(2A-9) and eSrtA(4S-9) with a 51,000- or 120-fold 
change in substrate specificity, respectively.  eSrtA(2A-9) and eSrtA(4S-9) both have catalytic 
activity comparable to that of eSrtA, but strongly prefer LAXTG and LPXSG substrates, 
respectively, over the wild-type LPXTG substrate.  We demonstrated the utility of SrtA 
reprogramming by showing that eSrtA(4S-9), unlike eSrtA or wild-type SrtA, is capable of 
modifying the human protein fetuin A in unmodified human plasma with high efficiency and 
specificity.  We further demonstrated the utility of these reprogrammed sortases by using them to 
synthesize the bioconjugates Alexa Fluor® 750-LAETG-FGF1-PEG and Alexa Fluor® 750-
LAETG-FGF2-PEG using a set of four different PEG building blocks, and by using these 
evolved enzymes to simultaneously and orthogonally functionalize GGG-linked surfaces with 
target peptides. 
The evolution of eSrtA(2A-9) and eSrtA(4S-9) revealed a number of biochemical 
features of the enzyme, including the role of the channel formed by A118, A104, I182, and V168 
in directing and coordinating transpeptidation.  While this channel had been implicated as part of 
the sorting signal binding groove in previous structural studies
18,34
, this study represents the first 
modification of these residues to retarget the specificity of the enzyme.  Our use of broad 
spectrum mutagenesis to identify biochemically valuable loci in the enzyme active site for 
further interrogation by site-saturation mutagenesis also proved a valuable strategy for the study 
and engineering of this structurally dynamic protein. 
The features of eSrtA(4S-9) suggest a complex mechanism underlying substrate 
specificity.  The high hydrolytic instability of the enzyme suggests that the thioester intermediate 
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is destabilized in this mutant, a feature that may play a role in its high substrate specificity by 
selectively hydrolyzing mis-charged enzyme.  In comparison, the very low hydrolytic instability 
of eSrtA(2A-9) suggests increased stability of the thioester intermediate, comparable to that of 
the wild type SrtA and increasing its potential utility for downstream applications in cases where 
GGG-linked substrates are difficult to access.  
In agreement with Piotukh et al
13‟s report of a promiscuous SrtA recognizing XPETG 
peptides, we observed that eSrtA is capable of evolving significant changes in substrate 
specificity.  This capability is somewhat surprising given the mechanistic similarity between 
sortases and cysteine proteases
18
 and the well-appreciated difficulty of successful engineering or 
evolving proteases with altered substrate specificities
35,36
.  Our successful reprogramming of two 
out of eSrtA‟s four specificity-determining amino acids suggests that it is unusually 
reprogrammable, making it an appealing target for the further evolution of user-defined protease-
like enzymes.   
 
The high activity and specificity of eSrtA(4S-9) enabled the successful chemical 
modification of the human serum glycoprotein fetuin A, the major carrier protein of calcium 
phosphate in vivo and a potent anti-inflammatory protein and inhibitor of soft tissue 
calcification
23
.  While fetuin A is traditionally difficult to purify away from its natively 
interacting partners
37
, our strategy of site-specific reaction and pull-down afforded pure 
preparations of truncated fetuin A without detectable contaminants.  Low levels of fetuin A are 
strongly associated with significant increases in all-cause mortality of patients undergoing 
hemodialysis regimens
24
, suggesting that the in situ enhancement of fetuin A bioavailability by 
e.g. PEG-ylation may improve outcomes in such patients.  Additionally, covalent modification of 
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fetuin A enables the direct study of its proposed roles in hepatocyte invasion by P. berghei
26
 and 
insulin sensitivity
38
.  
The milligram-scale synthesis of protein-PEG conjugates mediated by the sortases 
evolved in this study demonstrates the effectiveness of orthogonal transpeptidases in the rapid 
synthesis of complex biomolecules.  The combination of two orthogonal, high-activity enzymes 
enabled the facile synthesis of ten distinct fluorophore-FGF-PEG conjugates, five of them at 
milligram scale in a way that is not easily achieved by other existing methods of bioconjugation.  
Given the growing use of bioconjugates as human therapeutics
39-41
, we anticipate that this 
technique may prove useful in the rapid generation and testing of a wide variety of protein-small 
molecule and protein-polymer constructs. 
Finally, our use of orthogonal eSrtA variants for the synthesis of peptide-conjugated 
surfaces from complex starting mixtures illustrates the potential utility of our evolved SrtA 
variants for novel materials syntheses.  By enabling the specific and orthogonal conjugation of 
proteins and material surfaces, we anticipate that orthogonal evolved sortases will enable the 
construction of previously inaccessible materials containing multiple, homogenously 
immobilized proteins. 
The relative infrequency of any given peptide 5-mer among within a typical proteome 
means that any given SrtA-derived transpeptidase is unlikely to react with more than a small 
number of targets.  The successful demonstrations achieved in this study, coupled with the 
generality of our eSrtA reprogramming strategy, suggests that it should be possible to reprogram 
sortases to selectively target other proteins as well. 
Methods 
750-LAETG-FGF-LPESG-PEG Dual Labeling Protocol 
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SUMO-TEV Site-FGF-LPESG-His6 conjugates were treated with 0.2eq eSrtA(4S-9), 1mM 
GGG-PEG and 10mM CaCl2 in TBS and incubated at room temperature at 500μL final volumes.  
These samples were then quenched by the addition of 100μM H2NLPESGG peptide and 100μL of 
pre-equilibrated Ni-NTA resin slurry in TBS, then incubated on ice for 15 minutes.  This mixture 
was then passed through a 0.2μm spin filter, diluted 1:10 into PBS + 10μM H2NLPESGG peptide, 
and concentrated against a 10kDa MWCO spin concentrator to a final volume of 400μL.  This 
process was repeated five times to afford the crude SUMO-TEV Site-FGF-LPESGGG-PEG 
conjugates. 
These conjugates were then co-treated with 0.5eq TEV Protease, 0.2eq eSrtA(2A-9), 1mM 750-
LAETG and 10mM CaCl2 in TBS for 1 hour, then subjected to an identical purification process.  
This crude sample was separated into >30kDa fractions and <30kDa fractions by a 30 kDa 
MWCO spin concentrator to provide the conjugates in good purity.  Concentrations were 
determined by BCA assay 
Plasma Labeling of Fetuin A 
Normal human plasma was purchased from VWR (part number 89347-902), aliquotted to 1mL 
fractions and stored at -20°C.  For all reactions, an aliquot was thawed at 37°C for 15 minutes, 
then vortexed to resuspend any coagulated material.  To this sample was added 2 μL of 0.1M 
GGGK(Biotin) for analytical reactions.  Higher concentrations of GGGK(Biotin) were avoided 
for analytical purposes, as they are known to cause increased background in downstream 
Western blotting.  10μL of 1M CaCl2 was added in cases of calcium supplementation.  Reactions 
were initiated by the addition of 10μL of 100μM eSrtA, eSrtA(2A-9) or eSrtA(4S-9) and 
incubated at room temperature for 2 hours.  Reactions were quenched by 10:1 dilution into SDS-
PAGE loading buffer, followed by 10 minute incubation at 95°C.  These samples were then run 
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on 4-12% Bis-Tris PAGE gels, blotted to PVDF membrane using the iBlot2 dry blotting system, 
blocked with Pierce Superblock buffer for 1 hour followed by incubation with 1:500 dilutions of 
Abcam α-Fetuin A antibody (MM0273-6M23) in Superblock buffer with 0.1% Tween-20 for 1 
hour.  The blot was then washed 3 times with PBS + 0.1% Tween-20, then incubated again in 
1:15,000 LiCor goat anti-mouse 680 + 1:15,000 Licor Streptavidin-800 in Superblock buffer 
with 0.1% Tween and 0.01% SDS added for 45 minutes.  The blot was then washed 3 times with 
PBS + 0.1% Tween and visualized on an Odyssey IR imager. 
Materials Functionalization 
GGG-functionalized substrate was generated by incubating 100 μL, 2 μM of biotin-PEG (5K)-
GGG in streptavidin coated 96 well microplates (Pierce) for 2 hour at RT, and washed with 
TBST buffer (20 mM Tris, 100 mM NaCl, pH 7.5 with 0.05% Tween 20) for three times.  Then, 
GGG-well plates were reacted at RT with 100 μL of pools containing different enzymes (50 nM) 
and fluorophore-peptides (2.5 uM). For orthogonal specificity test, Alexa fluoro® 488–LAETG, 
Alexa fluoro® 647–LPESG or both were reacted with eSrt(2A-9), eSrt(4S-9), or both in the 
presence of 100 mM of CaCl2 in 25 mM Tris, 500 mM NaCl, pH 7.5.  After 2 hour, the well 
plates were washed with TBST for three times, and TBS buffer was added to each well. Then, 
the total fluorescent intensities were measured at 488 nm and 647 nm using Biotek Synergy NEO 
HTS Multi Mode microplate reader at Wyss Institute, Boston, MA. Experiments from three 
independents sets were averaged, and depicted in the graph after normalization.  
Yeast Contamination Cleanup 
Periodically, S. cerevisiae cultures would become contaminated with an unknown fungal growth, 
believed to originate from our laboratory HVAC system.  In spite of repeated attempts to scrub 
the contaminant using antifungal agents or altered media compositions, we were unable to 
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prevent its reemergence and eventual takeover of library cultures.  Thus, we chose a strategy of 
physical separation.  Whenever contamination was observed, each outgrowth of library material 
was centrifuged at 400xg for 30 minutes in a spinning bucket rotor against a step gradient of 
30%, 27.5% and 25% Ficoll-400PM in PBS.  Under these conditions, S. cerevisiae pelleted 
efficiently while contaminating organisms were isolated in the lower-density layers of the Ficoll 
gradient. 
Library Subcloning and Gene Isolation  
Following selections, yeast were grown to saturation (OD ~1.5) in SCD –Trp –Ura dropout 
media + 100 U/mL Penicillin, 100 μg/mL Streptomycin, 100 μg/mL Kanamycin at 30°C, then 
lysed using a Zymo Research Zymoprep II kit according to manufacturer‟s instructions.  The 
zymoprepped material was then either transformed directly  into NEB One-Shot Chemically 
Competent Top10 cells according to manufacturer‟s instructions, or PCR-ed by external primers 
HR2.Fwd and HR2.Rev, gel purified and then either mutated directly for another round of 
selection or digested by BamHI and XhoI and ligated into pre-digested pET29B vector, then 
transformed into NEB One-Shot Chemically Competent NEBTurbo cells. 
Chemical Mutagenesis Library Construction (rounds 1-3) 
Libraries were synthesized as in Chen et al (2011)
11
.  In short, genes were isolated from 
miniprepped yeast libraries by subcloning into Invitrogen chemically competent TOP10 cells, 
grown up in 25mL LB + 50 μg/mL carbenicillin, harvested by miniprepping and then 
mutagenized by PCR reactions containing 5μM 8-oxo-2‟deoxyguanosine (8-oxo-dGTP), 5μM 6-
(2-deoxy-b-D-ribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-C][1,2]oxazin-7-one (dPTP), 
200μM each dNTP, and 0.4 μM each of primers pCTCon2CTEV.HR2.F and 
pCTCon2CTEV.HR2.R.  Reactions were thermocycled ten times and the mutagenized genes 
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were further amplified in PCR reactions without mutagenic dNTP analogs using the same 
primers.  Gel-purified genes were combined with NheI/BamHI-digested pCTCon2CTev vectors 
in a 5:1 insert:backbone mass ratio and electroporated into ICY200 as described to yield the 
listed library sizes. 
Site Saturation Mutagenesis Library Construction (rounds 4-6) 
Genes were isolated from miniprepped yeast libraries by PCR, digested using restriction 
enzymes XhoI and BamHI, ligated into pre-digested pET29B vectors and then cloned into Life 
Technologies One Shot® Mach1 cells, grown overnight in liquid culture with 25 μg/mL 
Kanamycin and then harvested to afford the subcloned library.  100ng of this material was then 
subjected to PCR with either of two randomization primer pairs (round 4, 2A Library: 
104F/104R, 168+182F/168R; round 4, 4S Library: 104+118F/104R, 182F/182R; round 5, 2A 
Library: 162+168F/162R, 182F/182R; round 5, 4S Library: 118+122F/118R, 182F/182R; round 
6, 2A Library: 99+138F/99R, one of 160F/160R, 165F/165R, 189F/189R, 190F/190R or 
196F/196R; round 6, 4S Library: 132F/132R, one of 160F/160R, 165F/165R, 189F/189R, 
190F/190R or 196F/196R), then gel purified, treated with the NEBNext® End Repair Module 
according to manufacturers‟ instructions, blunt end ligated using NEB Quick Ligase according to 
manufacturers‟ instructions and then cloned into Life Technologies One Shot® Mach1 cells, 
grown overnight in liquid culture with 25 μg/mL Kanamycin and then harvested to afford the 
semi-random library.   
This was then repeated for the other randomization primer set in a given pair, and the products 
pooled and subsequently mutagenized by using the Stratagene Mutazyme II DNA mutagenesis 
kit for 25 cycles of amplification using primers pCTCon2CTEV.HR2.F and 
pCTCon2CTEV.HR2.R.  Reactions were then purified by spin column and combined with 
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NheI/BamHI-digested pCTCon2CTev vectors in a 5:1 insert:backbone mass ratio and 
electroporated into ICY200 as described to yield the listed library sizes. 
Primer Sequences: 
104F NNKgaagaaaatgaatcactagatgatcaaaatatttc 
104R aaagcttacacctctatttaattgttcagatgttgc 
168+182F
 NNKctagatgaacaaaaaggtaaagataaacaattaacattaNNKacttgtgatgattacaatgaagagacaggcgtttg 
168R ttctacagctgttggcttaacatttcttatacttg 
104+118F NNKgaagaaaatgaatcactagatgatcaaaatatttcaattNNKggacacactttcattgaccgtccgaactatc 
104R aaagcttacacctctatttaattgttcagatgttgc 
182F NNKacttgtgatgattacaatgaagagacaggcgtttg 
182R taatgttaattgtttatctttacctttttgttc 
99+138F
 gcaggacacactttcattgaccgtccgaactatcaatttacaaatcttaaagcagccaaaNNKggtagtatggtgtactttaaag
ttggtaatg 
99R
 aattgaaatattttgatcatctagtgattcattttcttcatgaaagcttacaccMNNatttaattgttcagatgttgctggtcctggata
tac 
132F NNK cttaaagcagccaaaaaaggtagtatggtgtac 
132R tgtaaattgatagttcggacggtcaatgaaagtg 
160F NNK aagccaacagctgtagaagttctagatgaacaaaaag 
160R atttcttatacttgtcattttatacttacgtg 
165F NNK gtagaagttctagatgaacaaaaaggtaaag 
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165R tgttggcttaacatttcttatacttgtcattttatac 
189F NNK gagacaggcgtttgggaaactcgtaaaatctttg 
189R attgtaatcatcacaagtaattaatgttaattg 
190F NNK acaggcgtttgggaaactcgtaaaatctttgtag 
190R ttcattgtaatcatcacaagtaattaatgttaattg 
196F NNK cgtaaaatctttgtagctacagaagtcaaactc 
196R ttcccaaacgcctgtctcttcattgtaatcatc 
Mutagenic PCR Library Construction (rounds 7-9) 
Genes were isolated from miniprepped yeast libraries by PCR, gel purified, and subsequently 
mutagenized by using the Stratagene Mutazyme II DNA mutagenesis kit for 25 cycles of 
amplification using primers pCTCon2CTEV.HR2.F and pCTCon2CTEV.HR2.R.  Reactions 
were then purified by spin column and combined with NheI/BamHI-digested pCTCon2CTev 
vectors in a 5:1 insert:backbone mass ratio and electroporated into ICY200 as described to yield 
the listed library sizes 
Alexa750-LAETG Synthesis 
25 mg Alexa Fluor® 750 NHS Ester was dissolved in 45μL of 0.4M H2NLAETGG peptide in 
DMSO and incubated at room temperature for 6 hours, at which point 2.5 μL DIPEA was added 
and incubated at room temperature overnight.  Reactions were quenched by the addition of 
450μL 1M Tris, pH 7.5, and were incubated on ice for 2 hours.  This reaction was purified on a 
preparative Kromasil 100-5-C18 column (21.2×250 mm, Peeke Scientific) by reverse phase 
HPLC (flow rate:  9.5 mL/min; gradient: 10% to 70% acetonitrile with 0.1% TFA in 0.1% 
aqueous TFA gradient over 30 minutes; retention time 8 minutes) before pooling and 
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lyophilizing the collected fractions.  The concentration of the peptide was determined by the 
known molar extinction coefficient of Alexa Fluor® 750, ε749nm = 290,000 M
-1 
cm
-1 
GGG-PEG Synthesis 
100mg 10kDa PEG-NH2, 10kDa bis-PEG-NH2, 10kDa 4-arm-PEG-NH2 or 10kDa Biotin-PEG-
NH2 was dissolved in 500μL dry dichloromethane, to which was added 250μL of a slurry 
composed of 164 mg Fmoc-Gly-Gly-Gly-COOH (BAChem), 132 mg of HATU and 56 mg of 
HOAt dissolved in 1mL dry DMF.  This mixture was sonicated for 20 minutes before the 
addition of 35μL DIPEA, then sonicated an additional 20 minutes before incubation at room 
temperature for 16 hours.  The mixture was quenched on ice by the addition of 100μL 
trifluoroacetic acid (TFA) then precipitated by addition to 10mL of cold diethyl ether and 
recrystallized twice from warm, absolute ethanol.  This material was filtered, dried under 
reduced pressure, then taken up in 1 mL 20% Piperidine/DCM and incubated at room 
temperature for 30 minutes.  This was quenched by the addition of 1mL TFA on ice, ethanol 
precipitated, and then recrystallized twice from warm, absolute ethanol. 
FGF Expression and Purification  
Codon-optimized FGF1 and FGF2 constructs were synthesized as gBlocks from Integrated DNA 
Technologies.  These were cloned via restriction digestion and ligation into pET29 expression 
plasmids with similarly optimized SUMO-TEV Cleavage site and LPESG- linkers at their N- 
and C-termini, respectively.  E. coli BL21(DE3) transformed with these plasmids were cultured 
at 37 °C in LB with 50 μg/mL kanamycin until OD600 = 0.5-0.8. IPTG was added to a final 
concentration of 0.4 mM and protein expression was induced for three hours at 30 °C. The cells 
were harvested by centrifugation and resuspended in lysis buffer (50 mM Tris pH 8.0, 300 mM 
NaCl supplemented with 1 mM MgCl2, 2 units/mL DNAseI (NEB), 260 nM aprotinin, 1.2 μM 
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leupeptin, and 1 mM PMSF). Cells were lysed by sonication and the clarified supernatant was 
purified on Ni-NTA agarose following the manufacturer‟s instructions. Fractions that were >95% 
purity, as judged by SDS-PAGE, were consolidated and dialyzed against Tris-buffered saline (25 
mM Tris pH 7.5, 150 mM NaCl).  Protein concentration was calculated from BCA assay. 
In Vitro SrtA Characterization 
Assays to determine kcat and Km LPETG were performed in 300 mM Tris pH 7.5, 150 mM NaCl, 5 
mM CaCl2, 5% v/v DMSO, and 9 mM Gly-Gly-Gly-COOH (GGG). The concentration of the 
LPETG peptide substrate ranged from 12.5 μM to 10 mM, and enzyme concentrations ranged 
from 25 nM to 1000 nM. Assays for determination of Km GGG were performed under the same 
conditions, except the LPETG peptide concentration was fixed at 1 mM, the enzyme 
concentration was fixed at 41.5 nM, and the concentration of GGG was varied from 0 μM to 100 
mM, depending on the enzyme. Reactions were initiated with the addition of enzyme and 
incubated at 22.5 °C for 3 to 20 minutes before quenching with 0.2 volumes of 5 M HCl. Five to 
ten nmol of peptide from the quenched reactions were injected onto an analytical reverse-phase 
Eclipse XDB-C18 HPLC column (4.6150 mm, 5 μm, Agilent Technologies) and 
chromatographed using a gradient of 10 to 65% acetonitrile with 0.1% TFA in 0.1% aqueous 
TFA over 13 minutes. Retention times under these conditions for the Abz-LPETGK(Dnp)-
CONH2 substrate, the released GKDnp peptide, and the Abz-LPETGGG-COOH product were 
12.8, 10.4, and 9.1 min, respectively. To calculate the percent conversion, the ratio of the 
integrated areas of the GK(Dnp)- CONH2 and Abz-LPETGK(Dnp)-CONH2 peptide Abs355 peaks 
were compared directly.  To determine kcat and Km,LPETG, reaction rates were fit to the Michaelis-
Menten equation using Microsoft Excel using the Solver add-in.  To determine Km,GGG and KH, 
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reaction rates were fit to the modified Michaelis-Menten v =  
             GGG + KH 
 GGG + Km,GGG
, for which KH  
is as defined when KH  << Km,GGG.  
Preparative Scale Biotinylation of Fetuin A 
As in analytical labeling of Fetuin A, 1 mL of normal human plasma was supplemented with 
10μL 1M CaCl2, a boosted concentration of 10μL 0.1M GGGK(Biotin) and 10μL eSrtA(4S-9), 
then incubated at room temperature for 2 hours.  100μL of pre-equilibrated Ni-NTA resin slurry 
and 12.5μL 0.4M H2NLPESGG peptide was then added to the mixture, the latter to act as a 
competitive inhibitor for thioester formation, and incubated at room temperature with shaking for 
15 minutes.  This was then filtered through a 0.2μm spin filter before dilution to 10mL final 
volume in PBS + 1mM EDTA + 100μM H2NLPESGG, and concentrated against a 10kDa 
molecular weight cutoff spin concentrator for 20 minutes at 3500xg and a final volume of <1mL.  
This was repeated six times to an expected small molecule biotin concentration of <1nM.  This 
was then incubated with 200μL of pre-equilibrated Invitrogen MyOne Streptavidin C1 
Dynabeads with shaking for 30 minutes before magnetic separation and washing three times with 
PBS + 0.1% Tween-20.  The beads were then resuspended in 100μL SDS-PAGE loading buffer 
with 100μM free biotin and incubated at 95°C for 15 minutes.  A 15μL aliquot was then run on a 
4-12% Bis-Tris PAGE gel, visualized by coomassie and excised with a clean razor.  This sample 
was then subjected to proteolytic digestion and analyzed by microcapillary reverse-phase HPLC 
nano-electrospray tandem mass spectrometry (μLC/MS/MS) on a Thermo LTQ-Orbitrap mass 
spectrometer by the Harvard Mass Spectrometry and Proteomics Resource Laboratory, FAS 
Center for Systems Biology, Northwest Bldg Room B247, 52 Oxford St, Cambridge MA. 
GGG-diblock Functionalization 
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GGG-functionalized amphiphilic diblock polypeptide (ADP) was used as a template for 
orthogonal reactivity test of the two evolved soratses in solution. A recombinant amphiphilic 
diblock polypeptide (ADP) derived from elastin-mimetic sequences,  
[(VPGVG)(VPGEG)(VPGVG)(VPGEG)(VPGVG)]10 for hydrophilic N-block and 
[(IPGVG)2VPGYG(IPGVG)2]15 for hydrophobic C-block, and prepared as previously reported 
(W Kim  DOI: 10.1002/anie.201001356; doi: 10.1016/j.actbio.2012.04.011). GGG-
functionalization of the ADP was achieved by conjugating Gly-Gly-Gly to N-terminal amine of a 
recombinant ADP via EDC-mediated carboxylate condensation.  In a 0.6 mL Eppendorf tube, 
GGG-functionalized ADP (10 μM) was mixed with fluorophore-peptide (0.1 μM), evolved 
sortase  (15 μM) and CaCl2 (100 mM), then reacted for 1 hour at RT.  Samples with different 
combinations of fluorophore-peptide conjugates (Alexa Fluor® 488-LAETG or Alexa Fluor® 
647-LPESG) and evolved sortases (eSrtA(2A-9) or eSrtA(4S-9)) were prepared for comparison 
of their cross-reactivity. Then, 4.7 μL of 4X SDS-PAGE loading buffer was added to 14 μL of 
reaction mixture, and incubated at 95°C for 3 minutes, and then run on a 15 % Tris-HCl Precast 
gel (BioRad) at 150 V for 60 minutes. After electrophoresis, fluorescent images were taken first 
without any staining using GE Typhoon FLA 7000 Gel Scanner at Wyss Institute at resolution = 
25 μm. Then, the gel was stained with coomasie blue to visualize protein bands containing GGG-
diblock and scanned.   
Enzyme Specificity Assay 
Assays to determine eSrtA(2A) and eSrtA(4S) specificity were performed by preparing 10µM 
stocks of LAETG, LPETG, LSETG, LGETG, LVETG, LPEAG, LPESG, LPETG, LPEVG and 
LPEGG in 300mM Tris pH 7.5, 150mM NaCl, 5mM CaCl2, 5% v/v DMSO, and 100 mM Gly-
Gly-Gly-COOH (GGG).  Reactions were performed by adding eSrtA(2A) to a final 
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concentration of 6.4, 64 or 640 nM, or eSrtA(4S) to a final concentration of 5.5, 55 or 550 nM 
and a final volume of 50µL, then incubating at 22.5 °C for 15 minutes.  Reactions were 
quenched by the addition of 0.2 volumes of 5M HCl, then were injected onto an analytical 
reverse-phase Eclipse XDB-C18 HPLC column (4.6150 mm, 5 μm, Agilent Technologies) and 
chromatographed using a gradient of 10 to 65% acetonitrile with 0.1% TFA in 0.1% aqueous 
TFA over 13 minutes. Retention times under these conditions for the Abz-LPETGK(Dnp)-
CONH2 substrate, the released GKDnp peptide, and the Abz-LPETGGG-COOH product were 
12.8, 10.4, and 9.1 min, respectively. To calculate the percent conversion, the ratio of the 
integrated areas of the GK(Dnp)- CONH2 and Abz-LPETGK(Dnp)-CONH2 peptide Abs355 peaks 
were compared directly. 
All other methods are as described in Chapter 2 
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